

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/46, 38/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/24371</b> <b>(43) International Publication Date:</b> 15 August 1996 (15.08.96)
<b>(21) International Application Number:</b> PCT/US96/01650 <b>(22) International Filing Date:</b> 8 February 1996 (08.02.96)  <b>(30) Priority Data:</b> 08/385,540 8 February 1995 (08.02.95) US 08/486,820 7 June 1995 (07.06.95) US  <b>(71) Applicant:</b> PHAIRSON MEDICAL, INC. [US/SE]; P.O. Box 15099, S-750 15 Uppsala (SE).  <b>(72) Inventors:</b> DE FAIRE, Johan; Bruksforvaltarvagen 18, S-740 33 Vattholma (SE). FRANKLIN, Richard, L.; 107 New Kings Road, Fulham, London SW6 4SJ (GB). KAY, John; 1 Sycamore Tree Close, Radyr, Cardiff CF4 8RT (GB).  <b>(74) Agent:</b> BLOOM, Allen; Dechert Price & Rhoads, Princeton Pike Corporate Center, P.O. Box 5218, Princeton, NJ 08543-5218 (US).	<b>(81) Designated States:</b> AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> MULTIFUNCTIONAL ENZYME  <b>(57) Abstract</b>  The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BK	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

### MULTIFUNCTIONAL ENZYME

The present invention relates to a krill-derived multifunctional enzyme and a family of crustacean and fish derived enzymes having substantial structural similarity to the multifunctional enzyme derived from antarctic krill.

- 5 The invention additionally relates to the multifunctional enzyme, to methods of purifying the multifunctional enzyme, to purified multifunctional enzyme and to pharmaceutical, cosmetic and other uses of the multifunctional enzyme of the invention.

- The enzymes that are substantially structurally similar to the krill-  
10 derived multifunctional enzyme have the same utility as the krill enzyme. In particular, these multifunctional enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds,  
15 immune disorders including autoimmune disease, such as lupus erythematosus and multiple sclerosis, and cancer.

- U.S. Patent Nos. 4,801,451 and 4,963,491 disclose a mixture of exo- and endopeptidases isolated from antarctic krill (*Euphasia superba*) and the use of the mixture as cleaning solutions. U.S. Patent No. 4,801,451  
20 discloses the use of such enzymes to remove foreign matter and dead tissue from wounds. Patent Application WO 85/04809 discloses the use of krill enzymes as a digestion promotor. European Application EP-A1-0170115 discloses the use of krill enzymes to dissolve blood clots. All of these references employ impure or poorly characterized materials. A purified  
25 multifunctional enzyme is desirable to provide a pharmaceutically useful product.

### SUMMARY OF THE INVENTION

- The present invention provides a multifunctional enzyme that has been found to be useful in numerous medical and cosmetic contexts. In particular,  
30 the invention relates to an enzyme having multifunctional activity comprising

- 2 -

at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity, a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE, and substantial homology to krill-derived multifunctional hydrolase. Preferably, the enzyme has a molecular weight of

5 from about 26 kd to about 32 kd as determined by SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresis ("PAGE"), more preferably about 29 kd. Preferably, the enzyme is selectively reactive with cell-surface receptors such as proteins or glycolipids. Preferably, the enzyme is substantially purified. Preferably the enzyme has a purity with respect to

10 macromolecules of at least about 90%, more preferably least about 95%, more preferably about 97%, still more preferably about 99%, yet more preferably 99.7% with respect to macromolecules. Preferably, the enzyme has an N-terminal sequence comprising: I-V-G-G-X-E/D-B-X-X-X-X-Z/B'-P-Z/H-Q-B-X-B'/Z, wherein X is any amino acid, Z is an aromatic amino acid, B

15 is an amino acid having a C2 to C6 alkyl side chain, and B' is leucine or isoleucine. More preferably, all amino acids represented by X, Z or B are natural amino acids. Preferably, the enzyme has an N-terminal sequence comprising: I-V-G-G-X-E/D-B wherein X is any amino acid, B is an amino acid having a C2 to C6 alkyl side chain. Preferably, the enzyme is the krill-derived

20 multifunctional hydrolase. Preferably, the enzyme has the N-terminal sequence: I-V-G-G-N/M-E-V-T-P-H-A-Y-P-W-Q-V-G-L-F-I-D-D-M-Y-F (SEQ ID NO. 1). For the purposes of this application, "substantially pure" shall mean about 60% purity.

In another preferred embodiment, the multifunctional enzyme shall have

25 at least about 70% homology with the krill derived multifunctional hydrolase, more preferably at least about 80% homology, still more preferably at least about 90% homology, yet still more preferably at least about 95% homology. Homology measurements will score conservative substitutions as homologous. The krill-derived multifunctional hydrolase can be the

30 multifunctional enzyme. The krill-derived multifunctional hydrolase is 100%

- 3 -

homologous with itself.

The invention also provides a pharmaceutical composition comprising the multifunctional enzyme of claim 1 and a pharmaceutically acceptable diluent or carrier.

5       The invention further provides (a) methods relating to certain conditions using effective amounts of the enzyme described above, (b) compositions for use in such methods, (c) pharmaceutical compositions containing effective amounts of enzyme for use in such methods, and (d) uses of the enzyme composition for manufacturing a medicament for use in such methods. The  
10 methods are for:

(1)    treating or prophylactically preventing a microbial infection [e.g. viral such as: a herpes (e.g. HSV-1, HSV-2, herpes zoster or  
15       genital herpes infection), HIV, hepatitis, influenza coronavirus, cytomegalovirus, rhinovirus or papilloma virus infection; an infection causing a gastrointestinal disease such as ulcer or  
diarrhoea; a fungal infection such as a systemic, skin , oral, vaginal or esophageal fungal, including, for example, yeast  
infection, including a fungal nail infection and candida infections; microbial infections of the eye, preferably treated with ocular  
20       administrations; bacterial infections including staphylococcus, streptococcus, klebsiella, pseudomonas, gonorrhea, haemophilus, chlamydia, syphilis and E. coli infections and bacterial infections causing chancroid; opportunistic microbial infections in immuno-  
compromised patients where preferably the administered amount  
25       of the multifunctional enzyme, described below, is a microbial infection treating or preventing effective amount or has inhibitory activity against cell-cell or cell-virus adhesion;

(2)    treating or prophylactically preventing dermatological conditions, such as, for example, acne, psoriasis or eczema, including facial  
30       seborrheic eczema or eczema of the hands, face or neck,

- 4 -

- hemorrhoids and the like, where preferably the amount of the multifunctional enzyme administered is a dermatological condition treating or preventing effective amount;
- 5 (3) treating or prophylactically preventing cystic fibrosis, COPD, cancer, for example, by administering a tumor treating effective amount or a tumor metastasis preventing or inhibiting amount of enzyme, atherosclerosis, asthma, septic shock, toxic shock syndrome, tissue adhesions such as tendon-sheath, abdominal post-surgical or joint adhesions, reperfusion injury, malaria, 10 immune disorder such as an autoimmune disease, apoptosis, colitis and enteritis, such as Crohn's disease, where preferably the amount of the multifunctional enzyme administered is effective for treating or preventing;
- 15 (4) treating or prophylactically preventing wound infection (by applying to the wound a microbial infection preventing effective amount of the enzyme or by enhancing the healing of the wound by administering a microbe inhibiting effective amount of the enzyme), when treated the wound can be substantially free of necrotic tissue;
- 20 (5) treating or prophylactically preventing acute or chronic inflammation, where preferably the amount of the multifunctional enzyme administered is an acute or chronic inflammation treating or preventing effective amount;
- 25 (6) treating or prophylactically preventing an indication selected from the group consisting of pain, bronchitis, haemophilus influenzae infections, mycoplasma in lungs, foreskin infections, athlete's foot, fistulae infections, infected topical ulcers, gastric ulcers, navel infections in newborns, wrinkles, polyps, scars and keloids, lichen planus, boils, warts and allergic itch, prostatitis, 30 mastitis, gingivitis, sinusitis, arthritis and inflamed joints,

- 5 -

diarrhoea, eye disease, such as glaucoma or cataracts, and hair-thinness, where preferably the amount of the multifunctional enzyme administered is a treating or preventing effective amount;

5 (7) removing dead or peeling skin from otherwise healthy skin to improve the skin's appearance, where preferably the amount of the multifunctional enzyme administered is a dead skin removing effective amount;

10 (8) lysing blood clots, where preferably the amount of the multifunctional enzyme administered is a clot lysing effective amount; and

(9) removing dental plaque, where preferably the amount of the multifunctional enzyme administered is a dental plaque removing effective amount.

15 The method comprises administering a composition comprising a the multifunctional enzyme described above. The composition of the invention can also be used to remove dead or divergent cells.

The invention provides topical cosmetic composition comprising the multifunctional enzyme described above; and cream, gel or suppository

20 composition.

The invention also provides method of purifying the multifunctional enzyme described above to obtain a composition containing substantially no other proteins that bind a selected protease inhibitor other than the multifunctional enzyme, the method comprising the steps of:

- 25 (a) applying a composition containing the multifunctional enzyme to an ion exchange column;
- (b) eluting a first adsorbed material from the column with a first aqueous solution of first ionic strength  $I_1$ ; and
- 30 (c) eluting the multifunctional enzyme from the column with a second aqueous solution of second ionic strength  $I_2$ ;



- 6 -

- (d) applying the eluted multifunctional enzyme from step (c) to an affinity matrix comprising the protease inhibitor; and
- (e) eluting the affinity matrix with a third aqueous solution that destabilizes the interaction between the multifunctional enzyme and the protease inhibitor

5 wherein  $I_1$  is selected so that the first aqueous solution (i) elutes the first adsorbed material containing proteins that can bind to the protease inhibitor, but which proteins adhere to the anion exchange column more weakly than the multifunctional enzyme and, (ii) does not elute the multifunctional  
10 enzyme; and wherein  $I_2$  is greater than  $I_1$  and is selected so that the second aqueous solution elutes the multifunctional enzyme and substantially no other proteins that bind the selected protease inhibitor. Preferably, the selected protease inhibitor used in the affinity matrix is resistant to digestion by the multifunctional enzyme, such as is a mammalian trypsin inhibitor, for example,  
15 bovine trypsin inhibitor.

The invention further provides (a) methods relating to certain conditions using effective amounts of the enzyme described above, (b) compositions or substances for use in such methods, (c) pharmaceutical compositions containing effective amounts of enzyme for use in such methods, and (d)  
20 uses of the enzyme for manufacturing a medicament for use in such methods. The methods are for:

- (10) prophylactically preventing sexually transmitted microbial infection, such as candida such as an oral or vaginal candida infection, gonorrhea, chlamydia, syphilis, trichomonas, chancroid, HIV, herpes, papilloma or hepatitis infections, where  
25 the administering of enzyme described below occurs before, in conjunction with, or after sexual activity, preferably in an infection preventing effective amount;
- (11) prophylactically preventing a cold or influenza virus infection, where the enzyme is preferably administered to the lungs, nasal  
30

- 7 -

passages or sinuses on an animal at risk of infection in a microbial infection preventing effective amount;

- (12) treating or prophylactically preventing a primary or secondary microbial infection in a patient having leprosy, preferably administering in a primary or secondary infection treating or preventing effective amount;

- (13) treating a tissue, body fluid or composition of cells to remove or inactivate a cell adhesion component comprising, wherein the enzyme is administered to the tissue, body fluid or composition of cells, preferably a cell-adhesion component removing or inactivating effective amount or an immune rejection inhibiting amount of the enzyme is administered, preferably the tissue, body fluid or composition of cells is treated extra-corporally, although they may also be treated *in situ* in an animal;

- (14) cleaning a contact lens, preferably applying to the lens a lens cleaning effective amount of the enzyme, where the application can be done while the lens is in the eye;

- (15) treating or prophylactically preventing coronavirus, such as the coronavirus causing feline infectious peritonitis, cytomegalovirus, rhinovirus or papilloma virus (such as human papilloma virus) infection, where preferably a viral infection treating or preventing effective amount of enzyme is administered;

- (16) treating or prophylactically preventing HIV infection, preferably administering an HIV infection treating or preventing effective amount of the enzyme;

- (17) treating or prophylactically preventing an oral or esophageal fungal, including yeast infection, preferably by administering a microbial infection treating or preventing effective amount of the enzyme;

- (18) treating or prophylactically preventing a pseudomonas, lichen

- 8 -

- planus, candida, such as a vaginal or oral candida infection, gonorrhea, chlamydia, syphilis, trichomonas, or chancroid infection, preferably by administering a microbial infection treating or preventing effective amount of the enzyme;
- 5       (19) prophylactically preventing, diminishing or removing a corneal scar, preferably by administering a corneal scar preventing, diminishing or removing effective amount of the enzyme, preferably the enzyme is administered in conjunction with ocular surgery to prevent the formation of a corneal scar;
- 10       (20) treating or prophylactically preventing conjunctivitis, such as viral, bacterial or allergic conjunctivitis, preferably by administering a conjunctivitis treating or preventing effective amount of the enzyme;
- 15       (21) treating or prophylactically preventing a disease or cellular process selected from the group consisting of cystic fibrosis, COPD, atherosclerosis, asthma, toxic shock syndrome, reperfusion injury, colitis, enteritis and malaria-infection associated pain, preferably by administering a treating or preventing effective amount of the enzyme;
- 20       (22) prophylactically preventing or limiting reperfusion injury, preferably by administering a reperfusion injury preventing or limiting effective amount of the enzyme;
- 25       (23) treating or prophylactically preventing the process of apoptosis in cells at risk for apoptosis, such as T-cells in HIV patients, preferably by administering an apoptosis treating or preventing effective amount of the enzyme;
- 30       (24) treating or prophylactically preventing an autoimmune disease such as multiple sclerosis, rheumatoid arthritis, lupus erythematosus, vasculitis, temporal arteritis, primary biliary cirrhosis, active chronic hepatitis, ulcerative colitis or

- 9 -

- scleroderma, preferably by administering an autoimmune disease treating or preventing effective amount of the enzyme; and
- (25) treating hemorrhoids (for example, post-partum hemorrhoids) preferably by administering a hemorrhoids treating effective amount of the enzyme.

5

The method comprises administering a composition comprising a the multifunctional enzyme described above.

- The invention further provides (a) methods for treating or prophylactically preventing a cell-cell or cell-virus adhesion syndrome comprising administering an anti-adhesion effective amount of a hydrolase effective to remove or inactivate a cellular or viral acceptor or receptor adhesion component that is involved in the cell-cell or cell-virus adhesion,
- (b) compositions or substances for use in such methods, (c) pharmaceutical compositions containing effective amounts of enzyme for use in such methods, and (d) uses of the enzyme composition for manufacturing a medicament for use in such methods. Preferably, the syndrome comprises inflammation, shock, tumor metastases, autoimmune disease, transplantation rejection reactions or microbial infections. Preferably, (a) the syndrome is selected from the group consisting of microbial infection, immune disorder, cystic fibrosis, COPD, atherosclerosis, cancer, asthma, septic shock, toxic shock syndrome, conjunctivitis, reperfusion injury and pain, and (b) a cell surface receptor, associated with the cell-cell or cell-virus adhesion syndrome, selected from the group consisting of ICAM-1, ICAM-2, VCAM-1, CD4, CD8, CD11, CD18, CD28, CD29D, CD31, CD44, CD 49, CD62L, CD102 and asialo GM1 ceramide is removed or inactivated by the administered hydrolase.
- Preferably, a microbial infection is treated or prevented and the microbial infection is a herpes, HIV, hepatitis or papilloma infection; an infection causing colitis, ulcer or diarrhoea; a candida infection, such as an oral, vaginal or esophageal candida infection; a cold or influenza infection; a *pseudomonas*, *haemophilus*, *staphylococcus*, *streptococcus*, *klebsiella* or *E. coli* infection; a

30

- 10 -

primary or secondary infection of leprosy; or an infection causing conjunctivitis.

The invention further provides (a) methods treating or prophylactically preventing an infection by a drug-resistant microbe by administering a treating  
5 or preventing effective amount of the multifunctional enzyme described above, (b) compositions or substances for use in such methods, (c) pharmaceutical compositions containing effective amounts of enzyme for use in such methods, and (d) uses of the enzyme composition for manufacturing a  
10 medicament for use in such methods. Preferably, the microbe is a methicillin or quinilone-resistant bacteria. In another preferred embodiment, the microbe is a fungus, such as a fungus (e.g., a candida fungus) that is resistant toazole-type drugs such as fluconazole.

The invention further provides a pharmaceutical composition for removing or inactivating a cell-surface adhesion molecule comprising a cell-  
15 surface adhesion molecule removing or inactivating effective amount of a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to the krill-derived multifunctional  
20 hydrolase, and a pharmaceutically acceptable diluent or carrier.

The invention still further provides a pharmaceutical composition for treating or prophylactically preventing a cell-cell or cell-virus adhesion syndrome comprising a cell-cell or cell-virus adhesion syndrome treating or preventing effective amount of a composition comprising a multifunctional  
25 enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to the krill-derived multifunctional hydrolase, and a pharmaceutically acceptable diluent or carrier.

30 Preferably, the multifunctional enzyme of the invention has at least two

- 11 -

of the identified proteolytic activities, more preferably at least three, still more preferably at least four. Yet more preferably, the enzyme has all of the identified proteolytic activities. Preferably, the multifunctional enzyme has substantial anti cell-cell and cell-virus adhesion activity. Preferably, the  
5 multifunctional enzyme has substantial homology with the krill-derived multifunctional hydrolase.

In a preferred embodiment, HIV-infected patients are treated to slow the progression of the associated diseases by the process of (1) isolating T-cells from the patient, (2) treating the T-cells with a hydrolase effective to  
10 remove CD4, and (3) injecting the T-cells into the patient.

The method of treating tumors can be done by administering orally or parenterally, including but not limited to intravenously, intra-arterially, intraperitoneally, subcutaneously, intramuscularly or intra-tumorally. As a part of this embodiment, the invention provides a method of preventing or limiting  
15 tumor metastatic processes.

In one embodiment, the invention provides a method of inhibiting or prophylactically preventing the transmission of a pathogenic microbe by administering the multifunctional enzyme. Preferably, the multifunctional enzyme is applied to the portion of the body that comprises the primary  
20 transmission entryway for the microbe in question. In one preferred embodiment, a spray, ointment or wash is applied to a body orifice involved in sexual activity, for instance, to prevent HIV or hepatitis transmission. In another preferred embodiment, the multifunctional enzyme is applied to the upper airways, for example, via an aerosol, to inhibit or prevent the  
25 transmission of a cold virus, such as a rhinovirus or a corona virus.

In one aspect, the method of extra-corporeally treating a tissue, body fluid or composition of cells to remove cell adhesion components reduces the immune rejection of a tissue, body fluid or composition of cells that is transplanted from one individual to another. In another aspect, such treatments  
30 remove or inactivate the cell adhesion components found in the treated

- 12 -

tissue, body fluid or composition of cells involved a microbial infection.

In treating or prophylactically preventing septic shock or toxic shock syndrome by administering the multifunctional enzyme, appropriate routes of administration would include without limitation systemic administration. For  
5 vaginal infections associated with shock, vaginal flushes, creams, gels or suppositories will preferably also be used as a method of administration.

The invention further relates to a method of prophylactically preventing sexually transmitted disease by applying a microbial infection preventing effective amount of the multifunctional enzyme to a birth control device.

10 Further, the invention provides birth control devices comprising the multifunctional enzyme.

In inhibiting or preventing the process of apoptosis, or programmed cell death, the enzyme can be administered *in vivo* or *ex vivo*.

In a preferred embodiment of the invention, the multifunctional enzyme  
15 is isolated in a form that is essentially free of any trypsin inhibitor. By "essentially free", it is meant that no such trypsin inhibitor is detectable by Coomassie Blue staining when 15  $\mu$ g of isolated multifunctional enzyme is analyzed by SDS-PAGE. Preferably, no trypsin inhibitor is detectable by silver staining when 1  $\mu$ g isolated multifunctional enzyme is analyzed by SDS-PAGE.

## 20 BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1A and 1B show the temperature stability of the poly-enzyme preparation of Example 1A when incubated at various temperatures over time scales of hours or days.

Fig. 2 shows the temperature optimum of the poly-enzyme preparation  
25 of Example 1A.

Fig. 3 shows the pH stability of the poly-enzyme preparation of Example 1A.

Fig. 4 shows the weight gain of mice having a soft ovarian-derived tumor that were either untreated or treated with the multifunctional enzyme  
30 purified as described in Example 1C.

- 13 -

Fig. 5 shows the survival of the enzyme-treated and untreated mice containing the ovarian tumor.

Fig. 6 shows the increase in time between urinations for urinary bladder infection patients treated with a poly-enzyme preparation of Example 1A.

5 Fig. 7 shows the reduction in erythema/swelling in patients with viral lung infections treated with the multifunctional enzyme purified as described in Example 1B.

Fig. 8 shows the protective effect of the multifunctional enzyme, purified as described in Example 1C, against HIV.

10 Fig. 9 shows the pH dependence of the multifunctional enzyme, purified as described in Example 1C, when tested against different substrates.

Fig. 10 shows the titration of the activity of the multifunctional enzyme, purified as described in Example 1C, with 2 different protease inhibitors.

15 Fig. 11 shows the pain relief experienced by lame race horses treated with the poly-enzyme preparation of Example 1A.

Fig. 12 shows certain indicators of healing following the treatment necrotic wounds with the multifunctional enzyme purified as described in Example 1B.

## 20 DETAILED DESCRIPTION

It has now been established that the multifunctional enzyme of the invention effectively removes or inactivates certain cell-surface adhesion molecules, such as ICAM-1 (i.e., CD 54), ICAM-2, VCAM-1, CD4, CD8, CD28, CD31, CD44 and the asialo GM1 ceramide, without affecting cell  
25 viability. This adhesion site removal or inactivation phenomenon is believed to provide at least a partial explanation for the enzyme's effectiveness against many, though probably not all, of the indications against which the multifunctional enzyme is effective. Other cell surface receptors have been found to be substantially resistant to removal or inactivation by the  
30 multifunctional protein, such as the T-cell receptor, the Class I major



- 14 -

histocompatibility complex or the integrins CD11 and CD18.

While not wishing to be restricted by any particular theory, it is believed that the activity of the multifunctional enzyme in preventing or treating infections by cold viruses relates to the enzyme's anti-adhesion activity. For instance, rhinoviruses, which are responsible for the majority of colds, infect by a pathway that utilizes an interaction between virus and ICAM-1 cell-surface adhesion molecule. See Lineberger et al., *J. Virol.* 64:2582-2587 (1990); Stauton et al., *Cell* 61:243-254 (1990). The multifunctional enzyme removes or inactivates ICAM-1 from mammalian cell surfaces. Analogously, the infective pathway for coronaviruses, which are responsible for most colds not caused by a rhinovirus, utilizes the CD13 cell-surface molecule. See Delman et al., *Nature*, 357:417-420 (1992); Yeager et al., *Nature*, 357:420-422 (1992). It is believed that multifunctional enzyme removes or inactivates a cell surface adhesion molecule involved in the infective pathway for coronaviruses. Because of the multifunctional enzyme's stability and the broad pH range over which it is effective, the enzyme can function in a number of environments, such as the lungs, sinuses, mouth, intestines and vagina, where it can be applied.

While not wishing to be restricted by any particular theory, the pain-relieving activity of the multifunctional enzyme in malaria is believed to be due at least in part to the enzyme's activity against the ICAM-1 cell-surface adhesion molecule. ICAM-1 is involved in adhering infected red blood cells (RBCs) to the endothelium and to uninfected RBCs, causing obstructions in the patient's capillaries and venules and the pain associated with the crises of malarial infections. Ockenhouse, "Cell Adhesion Molecules in Host Parasite Interactors" in *Adhesion Molecules*, Craig Wegner, Ed., Academic Press, San Diego, 1994, pp. 277-291. The multifunctional enzyme removes or inactivates ICAM-1 from cell surfaces.

A number of cell-surface adhesion molecules are involved in reperfusion injury, including the ICAM-1 molecule. Korthius and Granger, "Pathogenesis

- 15 -

of Ischemial/Reperfusion," in *Adhesion Molecules*, Wegner, Ed., Academic Press, 1994, pp. 163-190. ICAM-1 specific antibodies interfere with neutrophil adherence to and migration into ischemic tissue, *Id.*, thereby limiting the role of neutrophils in re-perfusion injury. These antibodies can also limit the size of a myocardial infarction. *Id.* at 177, figure 8.17. The multifunctional enzyme interferes with ICAM-1 by removing it from the cell surface or by inactivating it.

Again not wishing to be limited by any particular theory, the anti-CD4 cell surface adhesion molecule activity of the multifunctional enzyme is believed to be responsible, at least in part, for the enzyme's HIV-transmission inhibitory activity. The HIV infective pathway utilizes the CD4 cell-surface molecule. See, Lentz, "Molecular Interaction of Viruses with Host-Cell Receptors," in *Adhesion Molecules*, Wegner, Ed., Academic Press, 1994, pp. 223-251 at p. 229.

In candida infections, the hyphal stage is believed to be more infective. Ligands on the candida fungi that possibly recognize a GalNAc $\beta$ (1-4)Gal carbohydrate structure on asialo-GM1 ceramides of the infection host, are believed to be involved in the process by which candida infect. Such ligand molecules may also be involved in the process by which candida yeast are converted to the hypal stage. In *pseudomonas* infections of the lungs, a bacterial cell-surface ligand that recognizes a GalNAc $\beta$ (1-4)Gal carbohydrate structure is believed to play a role in the lung infection pathway. Abraham, "Bacterial Adhesions," in *Adhesion Molecules*, Wegner, Ed., Academic Press, 1994, pp. 253-276. The same or similar glycolipid structure is believed to be involved in adhering several pathogens to the lungs, including *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Klebsiella pneumoniae* and certain isolates of *E. coli*. See, Krivan et al., *Proc. Natl. Acad. Sci. U.S.A.* 85: 6157-6161, 1988.

Wrinkled skin to a major part is caused by free radicals crosslinking collagen. The formation of free radicals is believed to be caused by the

- 16 -

interplay between dead or dying cells and bacteria, which find such cells to provide an excellent growth medium. While not wishing to be bound to a particular theory, it is believed that the anti-adhesion properties of the multifunctional enzyme decrease the adherence to skin of the bacteria

5 involved in free radical formation.

Bacteria flourishing on dead, dying or divergent cells are believed to produce toxins that play a role in hair thinning. The toxins trigger skin cells to produce factors such as tumor necrosis factor, which in turn affect hair growth negatively. While not wishing to be bound to a particular theory, it is  
10 believed that the anti-adhesion properties of the multifunctional enzyme helps to stabilize or reverse the hair thinning process.

CD4 and ICAM-1 are believed to be involved in T-cell apoptosis. *See*, Okazaki et al., *Cell. Immunol.* 156: 135-45 (1994). Again not wishing to be limited to a particular theory, it is believed that the anti-adhesion properties of  
15 the multifunctional enzyme play a role in inhibiting apoptosis.

Gastric ulcer is a disease that is often associated with bacterial infection with *helicobacter pylori*. While not wishing to be limited to a particular theory, it is believed that the multifunctional enzyme of the invention acts on ulcers by inhibiting bacterial attachment to the gastro-  
20 intestinal mucosa.

Studies on the destruction or inactivation of cell surface molecules on T-cell exposed to as little as 10  $\mu\text{g/ml}$  of the krill hydrolase for four hours at 37°C have determined that: CD3 and CD90 are largely unaffected; CD28, CD49, CD29D, CD18 and CD11 are significantly destroyed or inactivated,  
25 about 25% to about 40% reduction detectable antigen; CD54, CD102, CD44, CD31, CD62L, CD4, and CD8 are substantially destroyed or inactivated, generally about 70% to about 100% reduction in detectable antigen. Additionally, antibodies against asialo GM-1 have indicated reductions in the immunologically detectable amount of this ceramide in the  
30 membranes of lung epithelial cells following exposure to the multifunctional

- 17 -

enzyme of the invention. Further, such treatment of lung epithelial cells reduces the level attachment of *Pseudomonas* bacteria to the lung epithelial cells.

It is believed that the above discussed adhesion molecules and others will prove to play a role in a number of other diseases for which the multifunctional enzyme is an effective treatment or preventative agent.

For the purposes of this application, the terms listed below shall have the following meaning:

- |    |   |  |
|----|---|--|
|    | ● at risk of infection                                      | an animal is at risk of infection if some feature of its environment or medical history is correlated with an increased risk of one or more infections.  |
| 10 | ● cell-cell or cell-virus adhesion syndrome                 | a disease in which a receptor or acceptor cell adhesion component plays a role in the etiology of the disease, for instance by playing a role in the development, transmission, growth or course of the disease. |
|    | ● cell adhesion component involved in a microbial infection | a cell adhesion component used by a microbe to facilitate adherence to a tissue or cell at risk of infection.  |
| 15 | ● dermatological condition                                  | a condition relating to lesions of the topical surface of an animal, including without limitation the skin, the vagina and the surface of the eyes.  |
|    | ● derived from fish or crustacean                           | refers to an enzyme having the same sequence as an enzyme isolated from fish or crustacean.  |
|    | ● drug-resistant  | a microbe of a type that is or once was generally sensitive to given amounts of one or more antimicrobial agents but which is not sensitive to the agents or is only sensitive at significantly higher amounts.  |

- 18 -

- **hydrolase** an enzyme that degrades bonds formed by dehydration reactions such as amide, ester, or ether bonds. The term encompasses, but is not limited to, proteases such as trypsin and chymotrypsin.
  - **immune disorder** any disorder caused by an immune reaction to foreign substances, tissues or cells or to autologous or transplanted tissue. The term encompasses autoimmune diseases.
  - **krill-derived multifunctional hydrolase** a multifunctional enzyme having the same sequence as the enzyme isolated from krill having the properties of the protein described in Examples 1B, 1C and 1D. This enzyme is also referred to as the "krill multifunctional hydrolase" or the "krill multifunctional enzyme" or the "krill-derived multifunctional enzyme."
- 5
- **macromolecule** for determining purity, this means a biological polymer such as a protein, nucleic acid or carbohydrate of molecular weight greater than about 1000.
  - **microbes** bacteria, mycoplasma, yeasts, fungi, virus, protozoa, parasites (such as malaria parasites) and the like.
  - **multifunctional enzyme** an enzyme having activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity, a molecular weight between about 20 kd and about 40 kd, and substantial homology to krill-derived multifunctional hydrolase.
  - **necrotic tissue** a portion of tissue made up of dead or irreversibly damaged cells.
  - **protein** for the purpose of determining purity, this means a polypeptide of molecular weight greater than about 1000.
- 10
- **reactive with a cell-surface protein or glycolipid** means removes, destroys, inactivates or disables the detectable presence of the cell-surface molecule, by whatever mechanism.

- 19 -

- **reactive with a cellular or viral acceptor or receptor adhesion component** means removes, destroys, inactivates or disables a cell's or a virus' ability to interact with a cell, virus, ligand, group or molecule, regardless of the mechanism.
- 5    • **SDS-PAGE** means polyacrylamide gel electrophoresis of proteins in the presence of sodium dodecyl sulfate.
- **selectively reactive with a cell-surface protein** means removes, destroys, inactivates or disables certain cell-surface proteins on the surface of a cell but not others.
- **sexually transmitted microbial infection** any microbial disease that is transmitted during sexual contact.
- 10   • **substantial homology** at least about 60% sequence homology.
- **substantially no other proteins that bind a selected protease inhibitor** a composition contains substantially no other proteins that bind a selected protease inhibitor if such proteins comprise no more than about 5% w/w of the total protein in the composition.
- **systemic administration** an administration of a biological agent, such as the multifunctional enzyme, designed deliver the agent to the blood or other circulatory system (such as the lymphatic system) of an animal.
- 15   Crustaceans, including antarctic krill, are useful sources for the multifunctional enzyme of the invention. For instance, frozen krill can be homogenized in water or buffer, preferably containing an antimicrobial agent. The supernate, diluted if appropriate, can then be fractionated by ion
- 20   exchange chromatography (preferably anion exchange chromatography), gel filtration, chromatofocusing chromatography, or other traditional separation process. Preferably, however, some part of the separation process will include affinity chromatography using a matrix having attached molecules of a trypsin inhibitor, such as soybean trypsin inhibitor. The krill-derived
- 25   multifunctional hydrolase used in the invention can be desorbed from such a matrix by applying conditions that will destabilize the interaction between the hydrolase and the inhibitor. Such conditions include high salt, low pH or the

- 20 -

presence of denaturants such as urea. To add another selective process, the destabilizing condition can be applied to the matrix incrementally, as in a gradient. When affinity chromatography is used, it will preferably be followed with chromatography using a matrix having attached molecules of the

5 multifunctional enzyme used in the invention. This enzyme affinity step serves to remove molecules of trypsin inhibitor that leach off the first affinity matrix. By these methods, multifunctional enzyme with a purity in excess of about 95%, such as a purity of about 99.7% or more, can be isolated.

The multifunctional enzyme isolated from a non-krill source can be

10 compared to isolated krill multifunctional hydrolase for molecular weight, sequence, temperature or pH stability, temperature or pH optima and proteolytic specificity, or for other properties of the krill-derived multifunctional enzyme exemplified in the examples.

Protease activity can be determined by incubating an enzyme

15 preparation with casein (concentration: 1% w/v) at 30°C for 20 hours and measuring the release of amino acids or peptides (which can be measured by the increase in colorometrically determinable amino groups). Isolated multifunctional enzyme of 95% purity will typically have a specific activity of at least about 25 Casein Units per mg. Casein Units are defined in *Biochem.*

20 *J.*, 173: 291-298, 1978 (using azocasein as the substrate).

Alternatively, tryptic protease activity can be measured against tyrosine-arginine-methyl-ester ("TAME"). The multifunctional enzyme (of at least about 95% purity) will preferably have specific activity of at least about 60 TAME Units per mg. Or, tryptic activity can be measured using

25 Benzoyl-Val-Gly-Arg-p-NO<sub>2</sub>-anilide as the substrate. Using this substrate and the method of *Biochemical J.*, 185: 423-433, 1980, the multifunctional enzyme will preferably have specific activity of at least about 210 Units per mg. Chymotryptic activity can be measured using Succinyl-Ala-Ala-Pro-Phe-p-NO<sub>2</sub>-anilide as the substrate. Using this substrate and the method of *J. Biol.*

30 *Chem.*, 269: 19565-19572, 1994, the multifunctional enzyme will preferably

- 21 -

have specific activity at least about 260 Units per mg. Elastase activity can be measured using Boc-Ala-Ala-Pro-Ala-p-NO<sub>2</sub>-anilide as the substrate. Using this substrate and the method of *J. Biol. Chem.*, 269: 19565-19572, 1994, the multifunctional enzyme will preferably have specific activity of at least  
5 about 270 Units per mg.

Protein purity is generally determined by SDS-PAGE with Coomassie blue staining. The percent staining in the appropriate band reflects the purity. Protein concentrations are generally determined by amino acid analysis or by absorbance at 280 nm.

10 Generally, the multifunctional enzyme will be sufficiently stable so that at least about 50% of the proteolytic activity is retained after incubation at 50°C for 24 hours at pH 7.0 at a concentration of 5 mg/ml. Preferably at least about 50% of the proteolytic activity is retained after incubation at 60°C for 5 hours at pH 7.0 at a concentration of 5 mg/ml.

15 Preferably, the pH optimum of the multifunctional enzyme is substrate dependent. For the substrate azocasein, the pH optimum is preferably from about 3.5 to about 6.5, more preferably, from about 4.0 to about 6.0. For the substrate Benzoyl-Val-Gly-Arg-p-nitroanilide, the pH optimum is preferably in excess of about 8.0, more preferably in excess of about 9.0. For the  
20 substrate Boc-Ala-Ala-Pro-Ala-p-nitroanilide, the pH optimum is preferably between about 6.0 and about 7.0, more preferably about 7.0.

Using Benzoyl-Val-Gly-Arg-p-nitroanilide as the substrate, the K<sub>m</sub> at about pH 9.5 in the presence of 2 mM Ca<sup>2+</sup> is preferably between about 200 and about 240 μM. Using Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as the  
25 substrate, the K<sub>m</sub> at pH 9.5 in the presence of 2 mM Ca<sup>2+</sup> is preferably between about 250 and about 290 μM.

Preferably, the multifunctional enzyme has a temperature optimum for activity against casein of between about 45°C and about 60°C. Generally, the enzyme retains at least about 50% of its activity when incubated at 5  
30 mg/ml for 18 hours at a pH ranging from about 5.0 to about 9.5 at 25°C.



- 22 -

When HL60 cells are pretreated with the krill multifunctional hydrolase, their binding to TNF $\alpha$  stimulated endothelial cells is inhibited by more than about 60%. Preferably, treatment of HL60 or endothelial cells with the multifunctional enzyme of the invention will inhibit HL60 cell binding to TNF $\alpha$  stimulated endothelial cells by at least about 20%, more preferably at least about 40%, still more preferably at least about 60%, yet more preferably at least about 80%. Alternately, the multifunctional enzyme will preferably have at least about 30% of the adhesion-inhibiting activity of the krill-derived multifunctional hydrolase. More preferably, the multifunctional enzyme shall have at least about 60% of the adhesion inhibiting activity of the krill-derived multifunctional hydrolase, still more preferably at least about 80%, yet more preferably at least about 100%.

The multifunctional enzyme of the invention is administered orally, topically, rectally, vaginally, by instillation (for instance into the urinary tract or into fistulas), by pulmonary route by use of an aerosol, by application of drops to the eye, or systemically, such as parenterally, including, for example, intramuscularly, subcutaneously, intraperitoneally, intraarterially or intravenously. The multifunctional enzyme is administered alone, or it is combined with a pharmaceutically-acceptable carrier or excipient according to standard pharmaceutical practice. For the oral mode of administration, the multifunctional enzyme is used in the form of tablets, capsules, lozenges, chewing gum, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like. In the case of tablets, carriers that is used include lactose, sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, and lubricating agents such as magnesium stearate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular weight polyethylene glycols. If desired, certain sweetening and/or flavoring agents are added. For parenteral administration, sterile solutions of the multifunctional enzyme are usually prepared, and the pHs of the solutions are suitably adjusted and buffered. For

- 23 -

intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic. For ocular administration, ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers. Such compositions can include

5 mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or polyvinyl alcohol, preservatives such as sorbic acid, EDTA or benzylchromium chloride, and the usual quantities of diluents and/or carriers. For pulmonary administration, diluents and/or carriers will be selected to be appropriate to allow the formation of an aerosol. For topical

10 administrations, the multifunctional enzyme is typically administered in aqueous form or in a hydrogel. A preferred hydrogel comprises an aqueous suspension of from about 1% (w/v) to about 10% of low molecular weight hydrolyzed starch.

Suppository forms of the multifunctional enzyme are useful for vaginal,

15 urethral and rectal administrations. Such suppositories will generally be constructed of a mixture of substances that is solid at room temperature but melts at body temperature. The substances commonly used to create such vehicles include theobroma oil, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weighty and fatty

20 acid esters of polyethylene glycol. *See*, Remington's Pharmaceutical Sciences, 16th Ed., Mack Publishing, Easton, PA, 1980, pp. 1530-1533 for further discussion of suppository dosage forms. Analogous gels or cremes can be used for vaginal, urethral and rectal administrations.

Numerous administration vehicles will be apparent to those of ordinary

25 skill in the art, including without limitation slow release formulations, liposomal formulations and polymeric matrices.

For topical treatments, a suitable dose of multifunctional enzyme per application ranges from about 0.1  $\mu\text{g}/\text{cm}^2$  to about 1  $\text{mg}/\text{cm}^2$ , preferably from about 1  $\mu\text{g}/\text{cm}^2$  (for example, using about 10  $\mu\text{g}/\text{ml}$ ) to about 1  $\text{mg}/\text{cm}^2$  (for

30 example, using about 10  $\text{mg}/\text{ml}$ ), more preferably from about 5  $\mu\text{g}/\text{cm}^2$  (for

- 24 -

- example, using about 50  $\mu\text{g}/\text{ml}$ ) to about 100  $\mu\text{g}/\text{cm}^2$  (for example, using about 1  $\text{mg}/\text{ml}$ ), yet more preferably from about 10  $\mu\text{g}/\text{cm}^2$  to about 250  $\mu\text{g}/\text{cm}^2$ , still yet more preferably from about 10  $\mu\text{g}/\text{cm}^2$  (for example, using about 100  $\mu\text{g}/\text{ml}$ ) to about 50  $\mu\text{g}/\text{cm}^2$  (for example, about 500  $\mu\text{g}/\text{ml}$ ). For
- 5 systemic treatments, dosages will generally be selected to maintain a serum level of multifunctional enzyme between about 0.1  $\mu\text{g}/100\text{cc}$  and about 5  $\mu\text{g}/100\text{cc}$ , preferably between about 0.5  $\mu\text{g}/100\text{cc}$  and about 2.0  $\mu\text{g}/100\text{cc}$ . In an alternative measure of preferred systemic administration amounts, preferably from about 0.1  $\text{mg}/\text{kg}$  to about 10  $\text{mg}/\text{kg}$ , more preferably about
- 10 1 $\text{mg}/\text{kg}$ , will be administered (although toxicology in animal models suggests that in excess of 25  $\text{mg}/\text{kg}$  is acceptable). For ocular treatments, a suitable dose of multifunctional enzyme per application ranges from about 0.01  $\text{mg}$  per eye to about 5  $\text{mg}$  per eye, preferably from about 0.1  $\text{mg}$  per eye to about 2.0  $\text{mg}$  per eye. For vaginal and urinary tract treatments, suitable
- 15 flushing/ instillation solutions of the multifunctional enzyme will generally have concentrations from about 1  $\mu\text{g}/\text{ml}$  to about 15  $\text{mg}/\text{ml}$ , preferably from about 100  $\mu\text{g}/\text{ml}$  to about 3  $\text{mg}/\text{ml}$ . For oral treatments, suitable mouthwash solutions will generally have concentration of multifunctional enzyme from about 1  $\text{mg}/\text{ml}$  to about 15  $\text{mg}/\text{ml}$  preferably from about 2  $\text{mg}/\text{ml}$  to about 10
- 20  $\text{mg}/\text{ml}$ . Lozenges will typically contain from about 100  $\mu\text{g}$  to about 10  $\text{mg}$  of multifunctional enzyme. Aerosols will generally be made from solutions having enzyme concentrations from about 0.1  $\text{mg}/\text{ml}$  to about 15  $\text{mg}/\text{ml}$ , preferably from about 1  $\text{mg}/\text{ml}$  to about 10  $\text{mg}/\text{ml}$ . Generally, from about 0.1  $\text{ml}$  to about 2  $\text{ml}$  of aerosol will be applied to the airways of the patient,
- 25 preferably from about 0.5  $\text{ml}$  to about 1.0  $\text{ml}$ . For scar and keloid treatments, generally between about 0.1  $\text{mg}$  and about 5  $\text{mg}$  of multifunctional enzyme will be injected into each  $\text{cm}^2$  of the lesion, preferably from about 0.5  $\text{mg}$  to about 3  $\text{mg}$ . For treating adhered connective tissue or joints, generally between about 0.5  $\text{mg}$  and about 10  $\text{mg}$  of multifunctional enzyme will be
- 30 injected interstitially at the adhesion, preferably between about 1  $\text{mg}$  and

- 25 -

about 5 mg. For all treatments, the enzyme composition will generally be applied from about 1 to about 10 times per day, preferably from about 2 to about 5 times per day. These values, of course, will vary with a number of factors including the type and severity of the disease, and the age, weight  
5 and medical condition of the patient, as will be recognized by those of ordinary skill in the medical arts. It is believed that substantially higher doses can be used without substantial adverse effect.

For treating or preventing infection, the multifunctional enzyme can be administered systemically or in a manner adapted to target the affected  
10 tissue. For preventing cold or influenza transmission, the composition is preferably applied to the lungs or airways. For treating immune disorders, the composition may be applied systemically or in a manner adapted to target the affected tissue. For treating the primary and secondary infections of leprosy, the primary administration route will generally be the topical route. For  
15 treating scar or keloid tissue, generally the composition will be injected into the scar or keloid, except that for corneal scars the composition will generally be applied ocularly without injection. For cancer treatment, the composition will generally be administered systemically by a route or in a manner adopted to target the affected tissue. For treating atherosclerosis, the composition  
20 will generally be administered systemically, although the site of administration may be chosen to administer the highest dosages to the portion of the circulatory system most at risk. For asthma, the general route of administration will be pulmonary. For treating pseudomonas infections, the infection will typically be a lung infection and the administration route  
25 pulmonary. For reperfusion injury, the composition will generally be administered systemically, although the site of administration may be designed to administer the highest dosages to the portion of the body that suffered an ischemic event. For treating the painful symptoms of malaria, the administration mode will generally be systemic.

30 For wound healing, the multifunctional enzyme is preferably be applied

- 26 -

more often than simply the time at which the wound is first dressed.

Preferably, the multifunctional enzyme is applied at least about every time the wound dressing is changed. The multifunctional enzyme can also be applied at least about every other day, more preferably, every day. In one

- 5 embodiment, the multifunctional enzyme is administered to a wound substantially free of necrotic tissue. The phrase "substantially free of necrotic tissue" shall mean sufficiently lacking in necrotic tissue so that an ordinarily-skilled pathologist would consider any residue of necrotic tissue to be irrelevant to determining a wound-healing prognosis.

- 10 For organ transplants, the organ to be transplanted will preferably be bathed in a solution of the multifunctional enzyme for between about 10 minutes and about 5 hours. The enzyme solution will preferably contain between about 0.01 mg/ml and about 25 mg/ml of the multifunctional enzyme, more preferably, between about 0.5 mg/ml and about 5 mg/ml.

- 15 After transplantation, the multifunctional enzyme will preferably be administered systemically using the conditions described above.

- For cleaning contact lenses *in situ* the solutions described above for ocular treatments are preferred; For *ex vivo* treatments, higher concentrations of enzyme will generally be used. Cleaning incubations of  
20 from about 5 to about 30 minutes at from about 20 °C to about 50 °C are also preferred. For *ex vivo* treatments, the higher end of the temperature range is preferred.

- For leprosy, many of the associated infections will be appropriately treated with a topical application of the multifunctional enzyme. For CF or  
25 COPD, the multifunctional enzyme can be used to treat (a) the build up of viscous fluids in the lungs and (b) associated pulmonary infections. Preferably, treatments of CF and COPD patients include pulmonary treatments with an aerosol of the multifunctional enzyme, but can include other routes of administration including systemic administrations.

- 30 Particularly important among the diseases relevant to the transmission

- 27 -

inhibitory embodiment of the invention are sexually-transmitted diseases, such as candida, gonorrhea, chlamydia, syphilis, trichomonas, chancroid, HIV, herpes or hepatitis infections. Among these, viral diseases are particularly preferred targets for transmission prevention; HIV is a still more preferred target. For this use, the body cavity involved in sexual activity is generally rinsed or flushed with a composition containing the multifunctional enzyme, or a creme, gel or suppository designed to localize the composition to the body cavity is used. The composition can be used soon before, in conjunction with, or soon after, sexual activity, although prior or concurrent use is preferred.

For herpes infections, the viral targets include HSV-1, which primarily manifests as oral herpes, HSV-2, which primarily manifests as genital herpes, and herpes zoster.

For autoimmune diseases or diseases with autoimmune components, treatment targets include without limitation rheumatoid arthritis, multiple sclerosis, primary biliary cirrhosis, active chronic hepatitis, ulcerative colitis, rheumatic arthritis, scleroderma, systemic lupus erythematosus, Hashimoto's thyroiditis, primary myxedema, thyrotoxicosis, pernicious anemia, Addison's disease, premature onset of menopause, autoimmune male infertility, insulin-dependent diabetes, type B insulin resistance of acanthosis nigricans, alopecia, allergy, myasthenia gravis, Lambert-Eaton syndrome, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, phacogenic uveitis, sympathetic ophthalmia, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, Sjogren's syndrome, discoid lupus erythematosus, dermatomyositis and mixed connective tissue disease.

For adhesion disorders, the cells or viruses involved can include, without limitation, endothelial cells, lymphocytes, including T-cells, tumor cells, microbial cells, viruses, including HIV and herpes. Adhesion processes are believed to be involved in tissue invasion, for instance, by immune cells, microbes, and tumor cells.

- 28 -

As illustrated in many of the clinical examples below, the multifunctional enzyme of the invention is effective to treat or prevent inflammation. Typically, inflammations are reduced to acceptable levels within 3 or 4 days of the start of treatment. The examples also illustrate that

5 the enzyme is effective to alleviate pain. Pain relief is often reported within 20 minutes to 2 hours of the start of treatment. Pain relief was not accompanied by loss of feeling in the treated tissue. More complete pain relief, such that the patient only suffered mild pain or a feeling of tenderness, was often experienced within 2 days of the start of treatment. While

10 measurement of this parameter is often subjective, the examples include treatments of inflamed horse joints, for which pain relief is more objectively measured by observing the walking stride of the treated horse.

For many of diseases for which the multifunctional enzyme of the invention is useful as a prophylactic treatment, including those not caused by

15 microbes, a patient's medical history, lifestyle or genetic background will often indicate a predisposition to acquire the disease. This is true, for instance, of atherosclerosis.

Preferred hydrolases are proteases. Particularly preferred is the multifunctional enzyme of the invention.

20 Generally, the multifunctional enzyme will be administered in an effective amount. An effective amount is an amount effective to either (1) reduce the symptoms of the disease sought to be treated, (2) induce a pharmacological change relevant to treating the disease sought to be treated, (3) inhibit or prevent infection or re-infection by an infective agent, or (4)

25 prevent the occurrence of a non-infectious disease (for instance a disease treatable by blocking a cell adhesion phenomenon). For cancer, an effective amount further includes an amount effective to: prevent or limit metastasis, for instance, to reduce the level of metastasis; reduce the size of a tumor; slow the growth of a tumor; and increase the life expectancy of the affected

30 animal. For wound treatment, in one aspect, an effective amount includes an

- 29 -

amount which, if regularly applied, prevents the occurrence of infection. In another aspect, for wound healing, an effective amount includes an amount effective to reduce the average time it takes for a wound to heal.

Humans are the preferred subjects for treatment. However, the  
5 multifunctional enzyme can be used in many veterinary contexts to treat animals, preferably to treat mammals, as will be recognized by those of ordinary skill in light of the present disclosure.

Numerous methods for determining percent homology are known in the art. One preferred method is to use version 6.0 of the GAP computer  
10 program for making sequence comparisons. The program is available from the University of Wisconsin Genetics Computer Group and utilizes the alignment method of Needleman and Wunsch, *J. Mol. Biol.* 48, 443, 1970 as revised by Smith and Waterman, *Adv. Appl. Math.*, 2, 482, 1981. Another available method uses the FASTA computer program.

15 The multifunctional enzyme has been observed to treat infections. However, its direct effect on the growth of microbes *in vitro* is small. While not wishing to be limited by any particular theory, it is believed that the enzyme attacks the mechanisms by which microbes and tumors invade tissues. These mechanisms include cell-cell or cell-virus adhesion  
20 mechanisms by which a tumor or microbe may establish itself in a tissue. The importance of cell-surface adhesion molecules and adhesion processes in tumor metastasis is illustrated by the discussion in a Albelda, "Role of Cell Adhesion Molecules in Tumor Progression and Metastasis," in *Adhesion Molecules*, Craig Wegner, Ed., Academic Press, San Diego, 1994, pp. 71-88.

25 The disruption of other cell-cell or cell-virus adhesion reactions by the multifunctional enzyme is believed to be relevant to other conditions that are treatable with the multifunctional enzyme, including dental plaque and immune disorders.

The adhesion of HL60 cells ( a hyman lymphocyte cell line) to  
30 endothelial cells is believed to model a mechanism for tumor cell invasion and



- 30 -

infection more generally. This adhesion is stimulated by tumor necrosis factor  $\alpha$  ("TNF $\alpha$ ") and inhibited by antibodies to the E-selectin antigen on HL60 cells. E-selectin is a cell surface adhesion protein that appears to bind to a sialated carbohydrate. See, Bevilacqua et al., *Science* (1989) 243:1160.

5       Preparations of the multifunctional enzyme are active even when not purified to homogeneity. In an illustrative purification set forth below in Example 1A, a "poly-enzyme" composition containing at least six proteins was prepared. This preparation was found to be active in numerous contexts, as illustrated in many of the examples.

10       At least one of the enzymes present in the poly-enzyme preparation is krill multifunctional hydrolase and has at least one of chymotrypsin, trypsin, elastase, collagenase or exo peptidase activity. This hydrolase can be substantially purified by traditional methods to an apparent purity of at least about 90%. The krill-derived multifunctional hydrolase displays an apparent  
15   molecular weight of about 29 kd.

Useful preparations of the poly-enzyme preparation will generally comprise, with respect to proteins, at least about 10% of the multifunctional enzyme. Preferably preparations of poly-enzyme preparation will comprise at least 30% of the multifunctional enzyme.

20       In Fig. 1 A and B, the temperature stability profiles the krill poly-enzyme preparation are displayed. Preparations of enzyme (5 mg/ml, buffered at pH 7.0) were incubated at 10, 20, 30, 40, 50, 60 or 70°C for various times and subsequently assayed for the ability to release amino acids and peptides from bovine casein (available from Bio-Rad Laboratories, Inc.,  
25   Hercules, California) after 20 hours incubation at pH 7.0. At 60°C, the preparation has a half-life in excess of 6 h; at 50°C, the half-life is well in excess of 24 h; and, at 40°C, the half-life is about 6 days. Fig. 2 displays a profile of the activity of the poly-enzyme preparation at various temperatures. The temperature optimum is 55°C. Fig. 3 displays a profile of the activity of  
30   the poly-enzyme preparation after incubation at room temperature at various

- 31 -

pH values. Following the incubation, the pH was adjusted to about pH 7.0, and the remaining activity determined as described above. The optimum stability is achieved at about pH 7.0. However, at least 50% of the original activity is retained following about 18 h incubations in solutions having pH values between about 5.0 and about 9.5.

The multifunctional enzyme can be purified from tissue homogenates of fish or crustaceans or from homogenates or supernates derived from a cell culture of transformed or normal prokaryotic or eukaryotic cells that produce the multifunctional enzyme. The preferred purification comprises the use of an affinity column comprising an inhibitor reactive with the multifunctional enzyme. After the multifunctional enzyme is eluted from the affinity column, residual enzyme inhibitor in the preparation is removed. One method of removal is to pass the preparation over an affinity matrix comprising a molecule, typically a protease, with which the inhibitor binds strongly (for instance, with an affinity constant of at least about  $10^6$  M, preferably at least about  $10^7$  M). More preferably, the affinity ligand is a previously isolated preparation of the multifunctional enzyme that the procedure seeks to purify.

Some amount of traditional protein purification will preferably be done prior to the affinity chromatography step. This can include differential precipitation, gel filtration chromatography, ion-exchange chromatography, chromatography on weakly hydrophobic matrices such as dye matrices, chromatofocusing and reversed phase liquid chromatography. Preferably, these one or more steps will be sufficient to remove all proteins, other than the multifunctional enzyme, that bind to the affinity ligand. Alternatively or supplementally, one or more traditional protein purification steps can be applied after the affinity chromatography step.

A preferred purification procedure comprises the steps of:

- (a) applying a composition containing the multifunctional enzyme to an ion exchange column;
- (b) eluting a first adsorbed material from the column with a

- 32 -

- first aqueous solution of selected ionic strength  $I_1$ ; and
- (c) eluting the multifunctional enzyme from the column with a second aqueous solution of selected ionic strength  $I_2$ ; and
- wherein  $I_1$  is selected so that the first aqueous solution (i) elutes the first
- 5 adsorbed material containing proteins that can bind to the hydrolase inhibitor, but which proteins adhere to the anion exchange column more weakly than the multifunctional enzyme and (ii) not elute the multifunctional enzyme, and
- wherein  $I_2$  is greater than  $I_1$  and is selected so that the second aqueous
- 10 solution elutes the multifunctional enzyme and substantially no other proteins that bind a selected protease inhibitor.

The method also further comprises the steps of, after step (c):

- (d) applying the eluted multifunctional enzyme from step (c) to an affinity matrix comprising the protease inhibitor;
- (e) eluting the affinity matrix with a third aqueous solution
- 15 that destabilizes the interaction between the multifunctional enzyme and the protease inhibitor; and
- (f) collecting the eluted multifunctional enzyme.

These preferred methods surprisingly yield, after a few steps, homogeneous preparations of multifunctional enzyme.

- 20 The method optionally comprises the steps of, after step (f):

- (g) applying the second eluted solution to an affinity matrix having a prior preparation of the multifunctional enzyme; and
- (h) collecting the effluent from the enzyme-containing affinity
- 25 matrix, the effluent comprising the purified multifunctional enzyme.

- Preferably,  $I_1$  is about the ionic strength of 0.4M NaCl and  $I_2$  is about the ionic strength of 0.6 M NaCl. Preferably, the anion exchange chromatography is conducted at a pH between about 5.5 and about 7.5, more preferably between about 6.0 and about 7.0, yet more preferably about
- 30 6.2. Preferably, the anion exchange matrix comprises a polysaccharide-based

- 33 -

matrix comprising, in the swelled state, between about 0.05 mmol and about 0.6 mmol anion exchange sites per ml. Preferably, the matrix is a cross-linked dextran of the type sold under the tradename Sepharose. Preferably, the anion exchange groups comprise diethylaminoethyl (DEAE) or

5 quaternaryaminoethyl (QAE) groups, more preferably DEAE groups.

The affinity chromatography of steps (d)-(f) preferably further comprise, between steps (d) and (e), washing the inhibitor-containing column with a solution having ionic strength of at least about that of 0.5 M NaCl, more preferably of about 0.8 M NaCl, yet more preferably of about 1M NaCl. This

10 step and the prior eluting step will preferably be conducted at a pH between about 5.5 and about 7.5, preferably between about 6.0 and about 7.0. The eluting step (e) preferably comprises applying a buffer having pH of about 2 to about 4, preferably about 3. Alternately, it may preferably comprise applying a buffer having pH of at least about 8. The eluting buffer will

15 preferably have sufficient ionic strength to suppress weak ionic interactions with the affinity matrix.

Steps (g) and (h) of the method will preferably be conducted at a pH between about 5.5 and about 7.5, more preferably between about 6.0 and about 7.0. The buffer used in these steps will preferably have sufficient ionic

20 strength to suppress weak ionic interactions with the affinity matrix.

The matrix used to create the affinity matrices will preferably comprise a carbohydrate matrix such as cross-linked dextran (e.g., that sold under the tradename Sepharose) or agarose (e.g., that sold by Pharmacia, Sweden as "Sephacryl"). The matrix should have pore sizes sufficient to admit both the

25 affinity ligand that will be attached to the matrix and the multifunctional enzyme of the invention. Methods of synthesizing appropriate affinity columns are well known. See, for instance, Axén et al., *Nature*, 214:1302-1304, 1967.

Preferably, the affinity ligand is selected to be resistant to digestion by

30 the multifunctional enzyme under the conditions used in steps (d) and (e).

- 34 -

Such affinity ligands include bovine trypsin inhibitor. Using such an inhibitor, optional steps (g) and (h) are generally of less importance.

Isolations and partial sequences of various fish or crustacean hydrolases have been reported. A number of such reports are identified in

5 Table 1, below.

**Table 1 - Sequence Reports**

10	<b><i>Panæus vanameii</i> 1</b>	
	Sequence reported:	Van Wormoudt et al., <i>Comp Biochem. Physiol.</i> , 103B: 675-680, 1992 and Sellos and Wormhoudt, <i>FEBS</i> , 39: 219-224, 1992.
	Reported activities:	chymotryptic
	Apparent MW:	25kd
15	<b><i>Panæus vanameii</i> 2</b>	
	Sequence reported:	Van Wormoudt et al., <i>Comp Biochem. Physiol.</i> , 103B: 675-680, 1992.
	Reported activities	chymotryptic (tryptic)
	Apparent MW:	25kd
20	<b><i>Panæus monodon</i> tryptic (shrimp)</b>	
	Sequence reported:	Lu et al., <i>Biol. Chem. Hoppe-Seyler</i> , 371: 851-859, 1990.
	Reported activities:	tryptic
	Apparent MW:	27kd
	Ph optimum:	7.4 - 8.0
	Pi:	≤ 2.4
25	<b><i>Panæus monodon</i> chymotryptic - 1 (shrimp)</b>	
	Sequence reported:	Tsai et al., <i>Biochem et Biophys. Acta</i> , 1080: 59-67, 1991
	Reported activities:	chymotryptic collagenase
	Apparent MW:	27-28kd

- 35 -

<b><i>Penaeus monodon</i> chymotryptic - 2</b>		
5	Sequence reported:	Tsai et al., <i>Biochem. et Biophys. Acta</i> , 1080: 59-67, 1991
	Reported activities:	chymotryptic collagenase
	Apparent MW:	25-26kd
<b><i>Uca pubilator</i> (Fiddler Crab) 1</b>		
10	Sequence reported:	Tsai et al., <i>Biochem. et Biophys. Acta</i> , 1080: 59-67, 1991
	Reported activities:	chymotryptic
	Apparent MW: Ph optimum	25kd 8.0 - 8.5
<b><i>Uca pugilator</i> II</b>		
10	Sequence reported:	Grant et al., <i>Biochemistry</i> , 19: 4653-4659, 1980.
	Reported activities:	chymotryptic collagenase tryptic elastase
	Apparent MW:	25kd
	pI:	8.0 - 8.5
<b><i>Kamchatka crab</i> (at least four proteases)</b>		
15	Sequence Reported:	Grant et al., <i>Biochemistry</i> , 22: 354-358, 1983
	Reported Activities:	tryptic collagenase
	Apparent MW:	23-26kd
<b>Crayfish Protease</b>		
20	Sequence reported:	Titani et al., <i>Biochemistry</i> , 22: 1459-1465,

The sequence of the first 25 amino acids of the Krill derived multifunctional enzyme is I-V-G-G-N/M-E-V-T-P-H-A-Y-P(W)-Q-V-G-L-F-I-D-D-M-Y-F (SEQ ID NO. 1). The parentheses indicate a weak recovery of the 14th amino acid and "N/M" indicates heterogeneity at the 5th position. A

- 36 -

comparison of the N-terminal 20 to 25 amino acid sequences of various serine hydrolases is presented in Table 2, below.

Table 2 - N-Terminal Sequences

	Species	SEQ ID NO	Sequence
5	<i>Penaeus vanameii</i> 1 (shrimp)	3	I V G G V E A T P H S W P H Q A A L F I D D M Y F
	<i>Penaeus vanameii</i> 2	4	I V G G V E A T P H S X P H Q A A L F I
10	<i>P. monodon</i> , trypt. (shrimp)	5	I V G G T A V T P G E F P Y Q L S F Q D S I E G V
	<i>P. monodon</i> , chym. 1	6	I V G G V E A V P G V W P Y Q A A L F I I D M Y F
15	<i>P. monodon</i> , chym. 2	7	I V G G V E A V P H S W P Y Q A A L F I I D M Y F
	<i>Uca pugilator</i> I (crab)	8	I V G G V E A V P N S W P H Q A A L F I D D M Y F
20	<i>Uca pugilator</i> II	9	I V G G Q D A T P G Q F P Y Q L S F Q D
	King crab	10	I V G G Q E A S P G S W P ? Q V G L F
25	Kamchatka crab	11	I V G G Q E A S P G S W P X Q V G L F F
		12	I V G G T E V T P G E I P Y Q L S L Q D
		13	I V G G T E V T P G E I P Y Q L S F Q D
		14	I V G G S E A T S G Q F P Y Q X S F Q D
	Crayfish	15	I V G G T D A T L G E F P Y Q L S F Q N
30	krill Enzyme	1	I V G G N E V T P H A Y P W Q V G L F I D D M Y F
		2	I V G G M E V T P H A Y P W Q V G L F I D D M Y F
	Bovine chymotrypsin	16	I V N G E D A V P G S W P W Q V S L Q D
35	Salmon	18	I V G G Y E C K A Y S Q A Y Q V S L N S G Y H Y C
	Atlant. Cod	19	I V G G Y E C T K H S Q A H Q V S L N S G Y H Y C
	Atlantic Cod	20	I V G G Y E C T R H S Q A H Q V S L N S G Y H Y C

X = unknown or undefined.

40

It will be apparent to those of ordinary skill that the enzyme can be manufactured by recombinant means. For instance, the sequences recited

- 37 -

herein can be used as the basis of oligonucleotide probes for screening expression or genomic libraries to isolate the complete structural gene. *See, e.g., Suggs et al., Proc. Natl. Acad. Sci. USA, 78: 6613, 1981 or Berent et al., BioTechniques, 3: 208, 1985.* Alternately, known protein sequences can be used to design primers for use in PCR-based amplification of nucleic acid encoding a multifunctional enzyme. *See generally, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor, 1989 and PCR Protocols, A Guide to Methods and Applications, edited by Michael et al., Academic Press, 1990.* Once fully identified, these structural genes can be edited and appropriately inserted into expression vectors by methods known to the art.

These structural genes can be altered by mutagenesis methods such as that described by Adelman et al., *DNA, 2: 183, 1983* or through the use of synthetic nucleic acid strands. The products of mutant genes can be readily tested for multifunctional enzymic activity. Conservative mutations are preferred. Such conservative mutations include mutations that switch one amino acid for another within one of the following groups:

1. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro and Gly;
2. Polar, negatively charged residues and their amides: Asp, Asn, Glu and Gln;
3. Polar, positively charged residues: His, Arg and Lys;
4. Large aliphatic, nonpolar residues: Met, Leu, Ile, Val and Cys; and
5. Aromatic residues: Phe, Tyr and Trp.

A preferred listing of conservative substitutions is the following:

Original Residue	Substitution
Ala	Gly, Ser
Arg	Lys
Asn	Gln, His
Asp	Glu



- 38 -

Original Residue	Substitution
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Ala, Pro
His	Asn, Gln
Ile	Leu, Val
Leu	Ile, Val
Lys	Arg, Gln, Glu
Met	Leu, Tyr, Ile
Phe	Met, Leu, Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp, Phe
Val	Ile, Leu

The types of substitutions selected can be based on the analysis of the frequencies of amino acid substitutions between homologous proteins of different species developed by Schulz et al., *Principles of Protein Structure*, Springer-Verlag, 1978, pp. 14-16, on the analyses of structure-forming potentials developed by Chou and Fasman, *Biochemistry* 13, 211, 1974 or other such methods reviewed by Schulz et al, *Principles in Protein Structure*, Springer-Verlag, 1978, pp. 108-130, and on the analysis of hydrophobicity patterns in proteins developed by Kyte and Doolittle, *J. Mol. Biol.* 157: 105-132, 1982.

Clinical trials with patients suffering from post-partum hemorrhoids have shown that 1 ml of hydrogel (of Example 1F) containing 500 µg/ml of the krill-derived hydrolase of Example 1C applied to the hemorrhoids three

- 39 -

times daily is effective to cure the hemorrhoid outbreak within two days, and usually within one day.

A double blind, placebo controlled trial with patients suffering from genital herpes has shown that 1 ml of hydrogel (of Example 1F) containing  
5 500  $\mu\text{g/ml}$  of the krill-derived hydrolase of Example 1C applied three times daily is effective to heal the sores of the herpes outbreaks within an average of 5 days. In patients treated with placebo, the outbreaks lasted an average of 12 days. In the patients treated with the hydrolase, pain and itching were gone within 36 hours, while these symptoms peaked at day 3 or 4 in the  
10 placebo controls.

Clinical trials with HIV patients suffering from oral candida have shown that a lozenge (of Example 1H) containing 3 mg of the krill-derived hydrolase of Example 1C applied three times daily is effective to clear the infection within 7 to 9 days.

15 Clinical trials with patients suffering from recurrent vaginal candidiasis that is resistant to traditional antifungal drugs have shown that 1 ml of hydrogel (of Example 1F) containing either 100  $\mu\text{g/ml}$  or 250  $\mu\text{g/ml}$  of the krill-derived hydrolase of Example 1C applied three times daily is effective to clear the candida outbreak within an average of four days and to reduce the  
20 recurrence rate.

A topical methicillin-resistant *Staphylococcus aureus* ("MRSA") infection characterized by necrotic tissue, erythematous and underlying tissues that were distended and edematous and affecting an approximately 100  $\text{cm}^2$  area has been effectively treated by applying 3 ml of hydrogel (of  
25 Example 1F) containing 500  $\mu\text{g/ml}$  of the krill-derived hydrolase of Example 1C three times daily. After application, the infection was covered by a dressing. By the third treatment on the second day, all necrotic tissue was removed, the erythema substantially reduced, and exudate flowed from the affected tissue. By day five, the edema was gone. By day seven, the wound  
30 was 40% closed, and the MRSA culture was negative. By day nine, the

- 40 -

wound was 75% healed.

Krill, including without limitation krill of the genres *Euphasia* (such as *superba*, *crystallorhynchus*, *frigida*, *triacantha*, *vellantini*, *lougirostris*, *lucens*, *similis*, *spinifera*, *recurva* and the like), *Meganyctiphanes* (such as *norvegica* and the like) and *Tysanoessa* (such as *macrura*, *vicina*, *gregaria* and the like), are a preferred source of the multifunctional enzyme.

The invention is exemplified with the following nonlimiting examples. Although in all of the examples the multifunctional enzyme derived from krill (i.e., the krill multifunctional hydrolase) was used, other multifunctional enzymes can be employed.

**Example 1A - Poly-enzyme preparation**

Frozen krill were thawed and homogenized. An equal volume of distilled water containing 0.02% (w/v) sodium azide was added, and the admixture stirred for about 6 hours at about 4°C. Then, the supernate was collected by centrifugation. The supernate was defatted by adding ethyl acetate and stirring overnight at 4°C. The fat-containing ethyl acetate layer was then decanted and the aqueous extract evaporated sufficiently to remove the ethyl acetate. Ammonium sulfate was added to the extract to about 60% saturation at about 4°C and the mixture stirred overnight. The salted out precipitate was isolated by centrifugation. The precipitate was dissolved in phosphate buffered saline ("PBS", 0.05 M sodium phosphate, pH 7.4, 0.05 M sodium chloride) and dialyzed (using a 10 kd molecular weight cutoff) against PBS.

The redissolved precipitate was applied to a cross-linked agarose gel filtration column (Sephacryl 200, Pharmacia, Sweden) and the fractions displaying absorbance at about 280 nm were assayed for proteolytic activity. The combined proteolytically active fractions were pooled and lyophilized. A "poly-enzyme" preparation containing about six bands with apparent molecular weights (by SDS PAGE) ranging from 24 to 34 kd were isolated from antarctic krill in this way. For storage, a lyophilized powder of this

- 41 -

preparation was aliquoted into ampules at 25 Casein Units per ampule.

**Example 1B - Preparation of krill-derived multifunctional enzyme**

A poly-enzyme preparation prepared as described in Example 1A was reapplied to a Sephacryl 200 column. A fraction that was sub-substantially homogeneous and displayed an apparent molecular weight of 29 kd was isolated. This fraction was found, using the proteolysis assays described below, to have multifunctional activity. The lyophilizate of this krill-derived multifunctional enzyme was placed into ampules at 15 Casein Units per ampule for sterile storage without preservatives or anti-microbial additives.

**10 Example 1C - Multifunctional Enzyme Purification**

A 100 kg of frozen antarctic Krill were thawed, and mixed with 100 kgs of distilled water, and stirred for 30 minutes. The krill used were harvested in the January through March period. During this period, krill are largely without pigment and are called "white" krill. (Due to dietary changes, later in the season krill are harvested as "red" krill. Multifunctional hydrolase yields from red krill are 30 to 40% less than from white krill. Still later in the season, during June through August, "black" krill are harvested. Black krill yield still less enzyme.) The supernate was collected by centrifugation using a GL-sieve, starch centrifuge (Model 220, available from G. Larssons Mekaniska Verkstad, Fjälkinge, Sweden) using a 125 micron spinning cone at 1,000 rpm. The pH of the supernate was adjusted to 6.2. The supernate had turbidity of less than 4% and fat content of less than 2%.

The supernate, 100 mls, was further clarified by centrifugation at 17,000 xg and mixed with 5 kg of DEAE-sepharose gel (Pharmacia, Sweden), which had been previously been equilibrated to pH 6.2. The mixture was stirred gently for 1 hour. The gel was collected on a filter bed and washed with 5 volumes of 0.4 M NaCl. The gel was then packed into a suitable column container using a 0.4 M NaCl saline solution. The column was then washed overnight with 15 bed volumes of 0.4 M NaCl.

A protein containing fraction (approximately 1.5 liters collected) was

- 42 -

- desorbed from the gel with 0.6 M NaCl. This fraction contained multiple proteins with molecular weights ranging from 10 kd to greater than 90 kd, as determined by SDS-PAGE. The protein content was 20 g/l, as determined by absorbance at 280 nm. The protein fraction was filter sterilized through a
- 5 0.20 micron filter and applied to an affinity column comprising soybean trypsin inhibitor coupled to agarose (200 ml of gel, substitution ratio 3:1 gel:inhibitor). The affinity gel was washed with 4 bed volumes of 1 M NaCl. The multifunctional enzyme was desorbed from the gel with 0.2 M sodium citrate, pH 3.0. (In parallel procedures, equivalent preparations of a
- 10 multifunctional enzyme were prepared by using either 0.5 M TRIS-HCl, pH 8.0 or 0.1 M ammonium solution, pH 11 to desorb the multifunctional hydrolase). The yield of multifunctional enzyme was 100 mg.

- The multifunctional hydrolase preparation was adjusted to pH 7.4 and applied to 200 ml of an agarose affinity gel to which a prior preparation of the
- 15 multifunctional enzyme had been coupled (6:1 substitution ratio gel:enzyme).

The purified multifunctional hydrolase preparation was homogeneous by SDS-PAGE. The purified preparation was filter sterilized and aliquoted into injection vials. The injection vials were freeze dried. The freeze-dried powder is stable when stored at 4°C.

20 Example 1D - Protein Characterization

- The krill-derived multifunctional hydrolase was purified by the protocol described above in Example 1C. Three preparations the krill-derived multifunctional hydrolase were prepared. The three preparations differed only in that the krill multifunctional hydrolase was eluted from the trypsin inhibitor
- 25 gel with buffer at pH 3, pH 8, and pH 11, respectively. These preparations shall be termed "Prep-3," "Prep-8," and "Prep-11." These preparations were dissolved in water to a concentration of 6 mg/ml.

- Samples of each preparation were analyzed by SDS-PAGE, and each preparation was found to contain a single protein that banded with apparent
- 30 molecular weight of 29 kd. The SDS bands were electroblotted onto PVDF

- 43 -

membranes and sequenced through 25 cycles of Edman degradation. See, Matsudaira, *J. Biol. Chem.*, 262: 10035-10038, 1987. Each preparation yielded the identical sequence: I V G G M/N E V T P H A-

Y P W Q V G L F I D D M Y F. Accordingly, it is clear that all three

5 preparations are homogenous, although each is micro-heterogeneous at position 5. The proteolytic activity of each of the three preparations was tested against substrate benzoyl-val-gly-arg-p-nitroaniline. Hydrolysis of this substrate can be monitored at 210 nm, reflecting the release of p-nitroaniline. The pH-dependence of the three preparations at an ionic strength of 0.1 M is  
10 shown in Fig. 9. The profile for Prep-3 (shown with filled squares), Prep-8 (shown with open diamonds) and Prep-11 (shown with filled diamonds) are identical. All three had a pH optimum for this substrate of 9.5.

With the elastase substrates succinyl-p-ala-pro-ala-p-nitroanilide and boc-ala-ala-pro-ala-p-nitroanilide, the pH optimum for Prep-8 was 7.0. See  
15 the profile in Fig. 9, represented by the X's. Similar model substrate studies determined that the order of cleavage efficiencies for the krill multifunctional hydrolase is chymotrypsin  $\geq$  trypsin  $\geq$  elastase.

For the substrate azocasein, the profile for pH dependence was broad and in the acidic pH region. See the profile in Fig. 9, represented by the open  
20 triangles.

$K_m$  values were determined using benzoyl-pal-gly-arg-p-nitroanilide in 0.1 M in CAPS buffer containing 2 mM  $Ca^{++}$  at pH 9.5. The  $K_m$  values for Prep-3, Prep-8 and Prep-11 were  $210 \pm 8$ ,  $210 \pm 8$  and  $230 \pm 13 \mu M$ , respectively. Against the substrate succinyl-ala-ala-pro-phe-p-nitroanilide,  
25 under the same conditions, the  $K_m$  values were  $260 \pm 50$ ,  $270 \pm 50$  and  $270 \pm 40 \mu M$ , respectively.

The effectiveness of three protease inhibitors was tested at pH 9.5 against the three hydrolase preparations. The results were as follows:

- 44 -

Protease inhibitor	Prep-3	Prep-8	Prep-11
	(% ACTIVITY REMAINING)		
Antipain (1 $\mu$ M)	2	5	5
Chymostatin (1 $\mu$ M)	0	0	0
5 Bovine pancreatic trypsin inhibitor (1 $\mu$ M)	2	1	1

The effectiveness of other protease inhibitors against Prep-8 was tested in a 0.1 M Tris-HCl buffer pH 7.5. Benzoyl-val-gly-arg-p-nitroanilide ("ARG-p-NA") and succinyl-ala-pro-phe-p-nitroanilide (Phe-pNA) were used as substrates. The results were as follows:

Inhibitor:	Substrate:	Phe-pNA	Arg-pNA
		(Activity remaining, %)	
Phosphoramidon (10 $\mu$ M)		94	87
15 Elastatinal (10 $\mu$ M)		100	100
Eglin C fragment (8.4 $\mu$ M)		100	Not done
Anti-Thrombin III (0.2 $\mu$ M)		2	4
$\alpha$ -anti-chymotrypsin (0.2 $\mu$ M)		1	7
20 $\alpha$ -proteinase inhibitor (0.2 $\mu$ M)		0	0

Aliquots of a solution of Prep-8, with a nominal concentration of 6 mg/ml, were titrated against either bovine pancreatic trypsin inhibitor,  $\alpha_1$ -antichymotrypsin,  $\alpha$ -protease inhibitor and soybean trypsin inhibitor. The results are displayed in Fig. 10. Profile 1 is for a titration of bovine pancreatic trypsin inhibitor tested at pH 9.5 using benzoyl-val-gly-arg-p-nitroanilide as the substrate. For profile 2, the pH was 7.0 and the substrate used was succinyl-ala-ala-pro-phe-p-nitroanilide. Similar profiles have been obtained with  $\alpha$ -antichymotrypsin,  $\alpha$ -protease inhibitor and soybean trypsin inhibitor. These curves can be used to estimate the  $K_i$  for the inhibitor and the effective concentration of multifunctional hydrolase.

- 45 -

**Example 1E - Hydrogel Preparation**

The multifunctional enzyme is mixed with a hydrogel made up of low molecular weight hydrolyzed starch containing 90% water by methods known in the art to obtain a hydrogel formulation of the enzyme.

**5 Example 1F - Hydrogel Preparation**

The multifunctional hydrolase according to Example 1B was mixed with hydrocolloid gel comprising an aqueous gel containing 0.8% w/v Carbopol™ (Dow Corning, Midland, Michigan) and 23.5% w/v glycerin prior to use. (Carbopol™ is a vinyl polymer with active carboxy groups described in *Chem.*

10 *Eng. News* 36:64 (1958).)

**Example 1G - Hydrogel Preparation**

The multifunctional enzyme according to Example 1C was mixed with hydrocolloid gel comprising an aqueous gel containing 0.8% w/v Carbopol™ (Dow Corning, Midland, Michigan), 23.5% w/v glycerin and 10% w/v Pluronic

15 P85 (BASF, Wyandotte, Michigan) prior to use. (Carbopol™ is a vinyl polymer with active carboxy groups. *Chem. Eng. News* 36:64 (1958).)

**Example 1H - Lozenge Preparation**

Lozenges containing 3 or 6 mg of the multifunctional enzyme according to Example 1C were formed from 50% lactose, 20%, Avicel (microcrystalline

20 cellulose), 29% sucrose and 1% magnesium stearate.

**Example 2 - Protease activity**

The multifunctional enzyme is compared to isolated krill multifunctional protease for molecular weight, sequence, temperature or pH stability, temperature or pH optima and proteolytic specificity.

**25 Example 2A - Specificity**

To study proteolytic specificity, the following substrates are used:

<u>Substrate</u>	<u>Type of Activity</u>
Succinyl-Ala-Ala-Pro-Phe-pNO <sub>2</sub> anilide	Chymotrypsin
Boc-Ala-Ala-Pro-Ala-pNO <sub>2</sub> anilide	Elastase

30



- 46 -

Benzoyl-Val-Gly-Arg-pNO<sub>2</sub>anilide

Trypsin.

These substrates are used to measure the proteolytic activities of the multifunctional enzyme in accordance with Example 1D. See, *Biochemical J.*, 185:423-33, 1980; *J. Biol. Chem.*, 269:19565-19572, 1994. These studies include measurements of  $K_m$  and  $K_{cat}$ .

#### Example 2B - Exo Peptidase Activity

The krill multifunctional hydrolase purified as in Example 1B (1 mg) was dissolved in 5 ml buffer together with 1% (wt/v) bovine casein and incubated at 20°C for 24 hours. The buffer was 0.1M sodium phosphate, pH 7.5. After 24 hours, 10% trichloroacetic acid was added to precipitate the proteins present in the solution. The supernate was collected and reacted with ninhydrin. The ninhydrin was used from a 2% solution in 3:1 DMSO: 4M Lithium Acetate, pH 5.2, as instructed by the supplier, Sigma Chemical, Co., St. Louis. The reacted supernate was applied to a cross-linked acrylamide column (Biorad P-2, Bio-Rad, Hercules, CA) to separate reacted amino acids from reacted peptides. The concentration of amino acids in the amino acid fraction was determined from the absorbance at 820 nm. A 1% solution of undigested casein was treated in the same way as a control. The control had an absorbance of less than 0.01, while the amino acid fraction of the digest displays an absorbance of 0.28 (at equivalent dilutions).

#### Example 2C - pH Optima

The multifunctional enzyme is tested for proteolytic activity against various substrates in solutions having various pH values between 4 and 10 to determine the pH optima against a given substrate, using buffer conditions that are well known in the art. These optima can be compared to the corresponding optima for the krill multifunctional hydrolase.

#### Example 2D - Protease Inhibitors

The effectiveness of various protease inhibitors is used to examine the relatedness of the various candidate multifunctional enzymes. These inhibitors are  $\alpha_1$  - protease inhibitor,  $\alpha_1$ -antichymotrypsin, anti-thrombin III,

- 47 -

$\alpha_2$ -macroglobulin, bovine pancreas protein inhibitor, and soybean protein inhibitor. Conditions for conducting such studies are described in Example 1D. These inhibitors are available from Sigma Chemical Co, St. Louis, MO.

- $K_i$  values are determined in solutions of various pHs using the following
- 5 protease substrates, including TAME, Benzoyl-Val-Gly-Arg-p-NO<sub>2</sub>-anilide, Succinyl-Ala-Ala-Pro-Phe-p-NO<sub>2</sub>-anilide, Boc-Ala-Ala-Pro-Ala-p-NO<sub>2</sub>-anilide and azocasein.

**Example 3A - In Vitro Binding of HL60 Cells to Endothelial Cells**

- Endothelial cells were first passaged onto 96 well plates at a given
- 10 concentration. The endothelial cells used in the experiment are described in Edgell et al., *Proc. Natl. Acad. Sci. USA* (1983) 80:3734. The cells were incubated at 37°C under a DMEM cell culture medium containing 10% fetal calf serum and under a 5% CO<sub>2</sub> atmosphere. Then, the medium was removed and replaced with 100 $\mu$ l of a suspension of 200,000 HL60 cells (a
- 15 human lymphocyte cell line, available from the European Cell Culture Bank under ECACC Accession No. 85011431) in RPMI medium containing 10% fetal calf serum. The cells were incubated for 30 minutes. After this, the medium was removed and the adherent cells were washed two times with DMEM medium. The relative adherence of the HL60 cells was measured by
- 20 measuring the difference in optical density at 450nm between the plates on which the cells were co-incubated and plates having endothelial cells alone.

- The effect of TNF $\alpha$  was measured by adding TNF $\alpha$  at 1500 units/ml to the endothelial cells 4 hours before the incubation with HL60 cells. The effect of antibody to E-selectin was measured by adding 25 $\mu$ g/ml of monoclonal
- 25 antibody BBAZ (R&D Systems Europe, Oxford, England) to the HL60 cells. The results of the experiments were:

- 48 -

Expt. No.	HL60 Cells	Endothelial Cells	Absorbance *
1	no treatment	no treatment	0.324
2	no treatment	pretreated with TNF $\alpha$	0.444
3	added in the presence of mAb to E-selectin	pretreated with TNF $\alpha$	0.357

5

\*increase over absorbance of endothelial cells alone

The effects of the krill multifunctional hydrolase on this system were measured by:

- 10 (1) measuring the effect of adding to the endothelial cells 92.3  $\mu$ g/ml krill multifunctional hydrolase (prepared as in Example 1C) together with the HL60 cells;
- (2) After pretreating the endothelial cells with TNF $\alpha$  for 2 hours, adding 92.3  $\mu$ g/ml krill multifunctional hydrolase and incubating
- 15 for 2 more hours prior to the addition of HL60 cells; or
- (3) Pretreating the HL60 cells with 92.3  $\mu$ g/ml krill multifunctional hydrolase prior to adding the HL60 cells to the plates of endothelial cells.

The results of these experiments were as follows:

20

Expt. No.	HL60 Cells	Endoth Cells	Absorbance *
4	Multifunctional enzyme added simultaneously with cells	pretreated with TNF $\alpha$	0.425
5	no treatment	Four hours pretreatment: 0-4h TNF $\alpha$ 2-4h multifunctional enzyme	0.247

- 49 -

Expt. No.	HL60 Cells	Endoth Cells	Absorbance*
6	pretreated with multifunctional enzyme for 2h	pretreated with TNF $\alpha$	0.160
7	pretreated with multifunctional enzyme for 2h	Four hours pretreatment: 0-4h TNF $\alpha$ 2-4h multifunctional enzyme	0.059

\*increase over absorbance of endothelial cells alone.

5

To confirm these results, the number of adhering HL60 cells were counted by removing them from the plate and counting the cells. The number of HL60 cells was determined by subtracting the cell numbers for control plates having only endothelial cells. These counting results mirrored

10 the optical density results, as follows:

EXPERIMENT	HL60 CELL NUMBER
1	32,590
2	43,990
3	35,730
4	42,190
5	25,280
6	17,010

15

These adherence studies show that krill hydrolase destroyed the cell-surface ligand and acceptor molecules that facilitate cell-adhesion.

20

**Example 3B - Activity Against Certain Cell-Surface Adhesion Molecules**

Freshly isolated T-cells from the thymus of a C57BL/6 mouse (bred by Institut Arnaud Frappier) were washed three times with serum-free medium. 1 ml aliquots of the cells containing 5 - 10 X 10<sup>6</sup> cells were treated at 37

- 50 -

°C for 4 hours with 0, 100 or 500 µg/ml of the krill-derived multifunctional hydrolase prepared according to Example 1B dissolved in serum-free medium. Resulting cells were labelled with one of fluorescent antibodies identified below:

5	Antibody	Source
	CD4-PE	Boehringer Mannheim, LaVal, Quebec
	CD8-Red613	GIBCO, Long Island, New York
	ICAM-1	PharMingen, San Diego, CA
	ICAM-2	PharMingen, San Diego, CA
10	CD44	PharMingen, San Diego, CA
	H-2K	PharMingen, San Diego, CA

The amount of antibody binding was determined using a fluorescence-activated cell sorter. From the results, it was determined that the order of sensitivity to inactivation or removal by the hydrolase was CD4, CD8 < ICAM-2 < CD44 < ICAM-1 < H-2K. Using these same methods with appropriate cells, including endothelial cells, including the s-end-1 endothelial cell line (Kinashi et al., *J. Leukocyte Biol.* 57: 168, 1995) and T-cells isolated from the thymuses of C57BL/6 mice, it was determined that the VCAM-1, CD28, CD 31 and asialo GM1 ceramide markers are sensitive to the hydrolase. The antibodies used to make these determinations were:

- 51 -

antibody specificity	source
VCAM-1	PharMingen, San Diego, CA
CD28	PharMingen, San Diego, CA
CD31	PharMingen, San Diego, CA
5 asialoGM1	Wako Bioproducts, Richmond, VA

In some cases, binding was detected with a labeled second antibody, for instance, binding of the asialo GM1 antibody was detected with FITC-labeled Fab fragments that were specific for rabbit IgG (heavy and light chains), which was obtained from Caltag Laboratories, San Francisco, CA.

**Example 3C - Timecourse of Cell Surface Recovery of Adhesion Molecules**

DO-11.10 T cell hybrids (this cell line is described by Shimonkevitz et al., *J. Experimental Med.* 158: 303, 1983) were treated with 500  $\mu$ g/ml of the krill-derived multifunctional hydrolase prepared according to Example 1B and tested for the CD4 marker as described in Example 3B. Immediately after the treatment, well less than 1% of the amount of CD4 found in the controls was found on the hydrolase-treated cells. 48 hours later, the levels in treated cells were the same as those in untreated cells.

**Example 4 - Cell Binding Comparisons**

The effectiveness of various members of the multifunctional enzyme family, i.e., the non-krill multifunctional enzymes having at least about 60% homology with the krill-derived hydrolase, are compared with that derived from krill using the HL60 binding assay of Example 3A.

**Example 5 - Mouse Ovarian Tumor Treatment**

25,000 mouse ovarian tumor cells were injected into the abdominal cavity of 12 C3H/hsd mice). On days 1, 2 and each of days 5-9, 1 ml of either saline or 200  $\mu$ g of krill multifunctional hydrolase (prepared as described in Example 1C) dissolved in saline was injected into the ascites. In Figure 4,

- 52 -

weight gains (an indication of tumor growth) for saline treated (dark circles) and hydrolase treated (open circles) mice are shown. In Figure 5, the percentage of the animals surviving over time for saline (line A) and hydrolase (line B) treated mice. Solid tumors formed in the control mice, but not in the enzyme-treated mice.

Tumor cells were recoverable from the ascites fluid of the treated mice. 25,000 such recovered tumor cells were injected into each of 6 C3H/hsd mice. In control experiments, the same number of untreated mouse ovarian tumor cells were injected into C3H/hsd mice. Tumors formed in the control mice, but not in the mice injected with recovered cells.

#### Example 6A - Toxicology

Separate groups of male and female rats (CrI:CD(SD) BR strain, Charles River Ltd, Margate, UK; 5 rats per group) were treated by the I.V. route with 0, 0.5, 5 and 50 mg/kg per day of the Krill-derived multifunctional hydrolase prepared according to Example 1C over 7 days. After seven days, these dosages resulted in small decreases in hemoglobin ("Hb"), red blood cell count ("RBC") and packed cell volume ("PCV"), as shown in the table below:

Group	Dose	Sex	HB	RBC	PCV	MCV*	MCH*	MCHC*
1	0	M	14.8	6.79	44.3	65.4	21.8	33.4
		F	14.7	6.76	43.7	64.6	21.7	33.6
2	0.5	M	14.0	6.35	41.8	65.9	22.2	33.6
		F	13.8	6.12	40.5	66.3	22.5	33.9
3	5	M	13.8	6.25	41.1	65.8	22.1	33.6
		F	13.4	5.94	39.9	67.2	22.6	33.6
4	50	M	13.1	6.19	39.1	63.3	21.3	33.6
		F	13.0	6.01	38.8	64.6	21.7	33.6

- \* MCV = mean corpuscular volume
- MCH = mean corpuscular hemoglobin
- MCHC = mean corpuscular hemoglobin concentration

- 53 -

None of the treated animals showed any visible symptoms of illness or adverse reaction.

#### **Example 7 - Toxicity on mice**

The toxicity of poly-enzyme preparation has also been tested on mice with s.c. implanted P388 murine leukemia (a chemically induced cancer) and compared with doxorubicin, a well known anti-cancer drug (abbreviation DOX). The results are summarized in the following Table. No mouse treated with the poly-enzyme preparation of Example 1A or in the control group died or lost weight, whereas all mice in the doxorubicin group, except for those receiving the lowest dosage, lost weight and died. The highest dose of poly-enzyme preparation (20 mg/kg) was far higher than any of the doses used in the clinical examples described below.

**Toxicity of poly-enzyme preparation and DOX administered i.p. daily during 9 consecutive days to mice with P388 murine leukemia**

Drug	Dose (mg/kg)	Toxic death	Body wt. chg. (g)
Control	0	0/6	+ 2.3
Krill poly-enzyme preparation	20	0/6	+ 3.3
	10	0/6	+ 3.3
	5	0/6	+ 3.3
DOX	5	6/6	- 2.3
	2.5	6/6	- 0.6
	1.25	0/6	+ 0.5

#### **Example 8A - Infections in post-operative surgical wounds**

Forty patients were included in this study and they were divided into two groups of 20 patients each, representing 41 post-operative abdominal (34) and thoracic (7) wounds. Preparations of krill multifunctional hydrolase prepared according to Example 1B (3 Casein-Units/ml), and krill poly-enzyme preparation of Example 1A (5 Casein-units/ml) were tested in each group.



- 54 -

The enzyme solutions were prepared from the ampule-stored lyophilized preparations described in Examples 1A and 1B, which were reconstituted in saline prior to use.

- 5 The patients had an average age of  $52 \pm 16$  years, and included 28 males and 12 females. Enzyme preparations were applied to the wounds 2 times daily in an amount of 25 mg/treatment. Within 5 days all infections were brought to a subclinical level and all apparent signs of clinical infections were gone. No notable difference between the two preparations could be observed. There were no apparent adverse reactions.

10 **Example 8B - Infected wound**

- A 3 month old boy who had been operated on for a hydro cele och scrotal hernia developed by 10 days after surgery a serious infection at the site of the incision. The infected incision exuded pus. Parts of the incision threatened to split open after the stitches were removed. The boy was  
15 treated twice daily for 3 days with dressings which had been soaked in the poly-enzyme preparation of Example 1A (4 mg per treatment). After 3 days of treatment the infection was gone and the wound had healed.

**Example 8C - Necrotic post-operative wounds**

- Fifteen patients with necrotic wounds were treated with 3 Casein  
20 Units/ml solutions of the krill multifunction hydrolase according to Example 1B. The wounds were cleaned by rinsing prior to applying the hydrolase. Twice daily an ampoule of the dry form of the multifunctional enzyme described in Example 1B was diluted in 5 ml saline and poured onto a gauze dressing which covered the wound completely. The drained gauze was fixed  
25 to the wound by a self-adhesive semi-occlusive dressing. At every change of dressing the wound was visually inspected for erythema, oedema, bleeding, swelling, heat, exudation, pus, necrotic tissue, pain, smell, possible adverse reactions and general status of patient. The treatment was terminated when all necroses, fibrin, pus and blood clots were decomposed but for no longer  
30 than 7 days.

- 55 -

The patient population was heterogeneous with respect to the etiology of the wounds, i.e. scheduled operations, traumas, burns, shots and diabetes patients. All patients were treated on an outpatient basis twice a day. No adverse reaction were observed from the test preparations. The results are  
5 summarized in Figure 12. The points indicated by "Y" symbols are for scoring of yellow fibrinous and purulent tissue. The points indicated by "B" symbols are for black necrotic tissue. And, the points indicated by "R" symbols are for granulation tissue and epithelium. Necroses, fibrin, pus, blood clots, and plaques were effectively decomposed within a week and some wounds healed  
10 within a week. Burns, shots, and post-operative wounds in diabetes-patient initially showed very poor efficacy, but at termination of the study, 7 days, the necroses were completely decomposed from underneath and what remained was only the top surfaces of the necroses, like a lid, and the wounds were partially healed within a week.

15 **Example 9 - Abscesses in calves**

Abscesses of approximately 25 to 40 ml volume were formed on the neck of each of two calves by injecting calcium-chloride solution. The abscesses were treated once daily by instillation of 10 ml of the poly-enzyme preparation of Example 1A (5 mg/ml) using a drainage tube. For each  
20 treatment, the tube was sealed to keep the enzyme solution in place for a minimum of 4 hours. Then the tube was then opened, allowing the abscess to drain. After the third treatment the drainage fluid was clear and after the sixth treatment the tubes were removed. The "pockets" healed completely after 9 and 12 days, respectively.

25 **Example 10 - Scleroderma**

The patient suffered from chronic hardening and thickening of the skin, i.e., scleroderma in his fingertips on his right hand. He was treated by twice daily applying 0.5 ml of hydrogel (described in Example 1F) containing 0.5  
30 mg/ml of the krill multifunctional hydrolase according to Example 1B. The pain associated with the condition was substantially reduced within 48 hours,

- 56 -

and after three weeks all cracks were healed. Treatment was discontinued after three weeks. No recurrence occurred during six weeks of follow up.

**Example 11 - Prophylactic treatment of post-surgical wounds**

Krill multifunctional hydrolase according to Example 1B (1) and krill  
5 poly-enzyme preparation of Example 1A (2) were tested against a sterile 0.9% NaCl control solution (3) as a prophylactic anti-microbial rinsing solution on post-op. wounds. Each of the treatment groups included 20 patients.

Non-bleeding post-operative wounds were treated twice daily with saline, multifunctional hydrolase (3 Casein Units/ml) or poly-enzyme  
10 preparation (5 Casein Units/ml). The wounds were rinsed thoroughly with the respective solution and covered with sterile gauze under a semi occlusive dressing. At each redressing, the wounds were inspected for infection, inflammation, erythema, swelling, heat, necrotic tissue, fibrin, pus, bleeding, pain and possible adverse reactions.

15 No post-operative clinical infections occurred in the groups treated with multifunctional hydrolase or poly-enzyme preparation, nor was acute inflammation or erythema observed in any of the patients in these two groups. For both groups treated with one of the enzyme compositions, 18 wounds were healed (>90% epithelialization) within 10 days treatment. No  
20 adverse reactions were observed. In the control group, 4 patients developed severe invasive infections and additional 2 patients developed acute inflammations. Erythema, swelling and pain were frequent observations in this group. In the control group, 14 wounds healed within 10 days of treatment.

**Example 12 - Small-sized burns**

25 Eleven patients with small, full thickness burns infected by *S. aureus* and *P. aeruginosa* and who did not respond to antibiotics and silver sulfadiazine cream were included in this study. 5 patients were treated with krill multifunctional hydrolase according in a hydrocolloid cream as described in Example 1F (3 Casein-Units/ml) and 6 patients with the krill poly-enzyme  
30 preparation of Example 1A in isotonic saline solution (5 Casein-Units/ml).

- 57 -

Wounds were treated two times daily with 25 mg/treatment of multifunctional hydrolase. All wounds were completely free from all signs of infection within 5 days treatment. The lack of infection was confirmed by microorganism (MO) cultivation. Necrotic tissue, pus and fibrinous fibrils in  
5 the granulation tissue were effectively decomposed by both preparations and no perceptible difference in efficacy between the preparations could be observed. No adverse reactions were observed. The test results were:

Wound No./ Size (cm <sup>2</sup> )	Strain	MO-status before (10 <sup>7</sup> )	Visual Percentage of					Day of termin.	MO-status after (10 <sup>7</sup> )	Visual percentage of				Healed day post- treatm.
			Necr.	Pus	Fibrin	Granul.	Epith.			Necr.	Pus	Fibrin	Granul.	Epith.
I 1.5	P.aerig.	16	20	60	20			Solution	3.5	<1			30	70
II 4.0	P.aerig.	18	50	10	40			Gel	5.0	<1		10	60	30
III 3.6	S.aureus	22	10	90				Gel	3.0	<1		10	40	50
IV 2.4	P.aerig.	14	40	10	50			Gel	3.0	<1			50	50
V 2.8	S.aureus	17		100				Solution	4.0	<1			30	70
VI 1.9	S.aureus	16		100				Solution	2.5	<1			20	80
VII 4.5	S.aureus	15	10	80	10			Gel	5.0	<1		10	60	30
VIII 3.2	P.aerig.	12	40	40	20			Solution	3.0	<1			60	40
IX 1.8	S.aureus	16	10	90				Solution	2.5	<1			20	80
X 1.3	P.aerig.	17	30	30	40			Gel	3.5	<1			40	60
XI 3.1	P.aerig.	20	30	30	40			Solution	5.0	<1		10	80	10
														18

5

10

15

20

25

- 59 -

**Example 13 - Infected decubitus ulcers**

Fourteen elderly patients with a total of 18 decubitus ulcers on their heels or lower back were included in this study. Ulcers were rinsed thoroughly with saline and emptied as much as possible and irrigated with 5 ml, krill poly-enzyme preparation of Example 1A dissolved in saline (5 Casein Units/ml). The ulcers were then covered with semi-occlusive dressing. The procedure was repeated twice daily for 7 days and ulcers were inspected for inflammation, erythema, heat, swelling, necrotic tissue, pus, pain and possible adverse reactions. Infections were gone within 4 days of treatment. Six wounds healed completely within 7 days, and a total of eleven have healed within 14 days. Seven wounds did not heal probably due to the overall condition of the patients, but the wounds showed some progress. No adverse reactions were observed.

**Example 14 - Fistulae infections**

Krill multifunctional hydrolase according to Example 1B and the krill poly-enzyme preparation of Example 1A were used to treat anal fistulae. Prior to use, one ampoule of the multifunctional hydrolase was reconstituted in 5 ml of hydrogel to a final concentration of 3 Casein-Units/ml. The poly-enzyme preparation was reconstituted in hydrogel to a final concentration of 5 Casein-Units/ml. The fistulae were rinsed with sterile solution and emptied as far as possible, and then irrigated with hydrogel containing multifunctional hydrolase or poly-enzyme preparation. The procedure was repeated once daily and patients were inspected for erythema, heat, swelling, pus, pain and adverse reactions. The treatment continued until all signs of infection and inflammation were gone, but for no longer than 10 days. For each gel preparation, two patients with anal fistulae, with no passages to rectum, were used and treated with multifunctional hydrolase and poly-enzyme preparation, respectively. For both sets of patients, total pain relief was reported within 48 hours and all signs of infections and inflammations were gone after 4 days. All fistulae were healed between day 6 and day 9, and no

- 60 -

recurrence was reported within 6 months of follow-up. No adverse reactions were observed.

**Example 15 - Athlete's foot (Epidermophytosis)**

The purpose was to study the effectiveness of krill poly-enzyme preparation treating epidermophytosis of the foot. Forty-one patients with fungal infections were included in this study. Patients soaked their feet for thirty minutes once a day for three successive days in an aqueous solution contain 5 Casein Units/ml of poly-enzyme preparation of Example 1A for 30 minutes. Also, a hydrogel (described in Example 1F) containing 5 Casein Units/ml of the krill poly-enzyme preparation was applied to the affected areas each evening immediately before bedtime for 7 nights. The pain relief was instant in many patients and pain was totally gone within 2 days for others. Plaques over open surfaces, in cracks and under nails were readily removed by the poly-enzyme preparation and all signs of plaque, smell and infections were gone after three days.

**Example 16A - Foreskin infection**

The foreskin infections of two infants, 4 and 6 weeks old, respectively, were treated twice daily with a solution of poly-enzyme preparation of Example 1A containing 1 Casein Unit/ml. 10 ml of the solution was flushed under the foreskin morning and evening, using a standard syringe with a soft catheter. After 3 days both the infants were free from symptoms and the infections did not recur during a 2 month follow-up.

**Example 16B - Foreskin infections in dogs**

Six dogs with foreskin infections were flushed under the prepuce once daily with a solution of poly-enzyme preparation of Example 1A containing 1 Casein Unit/ml. A soft silicone catheter attached to a syringe was inserted under the foreskin and used to slowly flush the affected area with 10 ml of the poly-enzyme solution. Approximately 1 ml of the solution was kept under the foreskin for minimum of 2 minutes and the dogs were kept from licking the affected area for 30 minutes. Purulent exudation stopped within 2 days

- 61 -

in all the cases and all signs of infection and inflammation were gone within 4 days.

**Example 17A - Opportunistic infections**

- Two patients with uterine cancer in stage IV with opportunistic
- 5 infections in non-healing post-operative wounds and one patient with an opportunistic infection of an irradiation wound were treated twice daily with dressings saturated with a solution of 5 mg/ml of the poly-enzyme preparation of Example 1A. The infections were believed to be bacterial infections. After 12, 14 and 17 days, respectively, the wounds had healed.

10 **Example 17B - Mycoplasma infection**

- A 55 years old man contracted an acute mycoplasma infection 3 years ago and was treated with different kinds of antibiotics. However, these treatments became ineffective when a resistant form developed. Some weeks after the infection the man contracted high fever with a very severe
- 15 cough as a result and in X-ray examination water in the pleura was observed. The complaints of the man manifested themselves in the form of respiration complaints, difficulty to walk longer distances than 100 meter without a break and severe tiredness as well as annoying hacking cough.

- The patient was treated with 2 mls of a 2 mg/ml solution (4 mg total)
- 20 of the krill multifunctional hydrolase according to Example 1B. The wash solution was kept in the mouth for about 4 minutes and then was slowly swallowed. This treatment was repeated during the first two weeks every second day. During this time, 0.5 ml of an aerosol of the wash hydrolase solution was inhaled on a daily basis. During the first two weeks no
- 25 improvement was observed but after two weeks' treatment the lymph gland on the left side of the neck swelled resulting in pain. During this time the treatment was continued 3 times (every second day). After 1.5 weeks all problems regarding the lymph nodes had disappeared and the bronchitis complaints of the patient began to subside. After further 3 weeks' treatment
- 30 with mouth washes every fourth day the bronchitis complaint had completely



- 62 -

disappeared. After this total treatment extending over 6.5 weeks the patient had recovered completely and after a short time he could walk 5 kilometers with no problems.

**Example 18 - Boils in dogs**

- 5           Three boxers with painful, infected and excudating/bleeding boils between the toes were treated twice daily with poly-enzyme solution. A gauze was soaked with 2 ml of a solution of poly-enzyme preparation of Example 1A (5 Casein Units/ml) and then applied over the boil. The paw was bandaged to keep the gauze fixed in place and a rubber boot was used to
- 10 protect the dressing. Apparent relief from pain was observed after 1 day of treatment. The flow of exudant and blood stopped within two days. After 5 to 7 days of treatment, inflammation was substantially reduced, and after 11 to 15 days, all indications of boils were gone.

**Example 19 - Urinary bladder and urethra infections**

- 15           Twelve female patients with painful urinary infections were included in this study. Before use, 6 ampoules of krill poly-enzyme preparation described in of Example 1A were reconstituted in 50 ml saline to a final concentration of 3 Casein-Units/ml. At the start of treatment, the first discharge of urine from all patients was very turbid and the second discharge was clear to
- 20 weakly turbid. Patients were treated with 50 ml of the saline solution by instillation 2 times daily. Pain relief was instant and improved ability to retain urine was obvious after two days of treatment. Micro-organism (MO) samples confirmed no bacteria after 4 days of treatment and all treatments were terminated after 4 days. No adverse reactions were observed. The
- 25 results are summarized in Figure 6. The average MO-status values are shown in the table below.

- 63 -

	BEFORE TREATMENT	DAY 2	DAY 4
MO Status: (average)	$1.4 \times 10^4$	$4.3 \times 10^3$	$< 1.0 \times 10^2$
5 Relative MO Status: (% of initial status)	100%	31%	1%

#### 10 Example 20 - Eye infections

Fifteen patients with purulent eye infections were treated twice daily with eye-drops of the poly-enzyme preparation from krill. Before use, an ampoule of poly-enzyme preparation as described in Example 1A was reconstituted in 25 ml water to a final concentration of 1 Casein-Unit/ml. The infected eye was treated morning and evening with two drops, 0.4 ml, of the solution. At each application, the eye was inspected for erythema, swelling, pus, lacrimal secretion and possible adverse reactions. The patient was treated until all signs of infection were gone, but not for longer than 10 days. All patients were free from infections within 3 days of treatment. Erythema and swelling around the eyes faded away within 2 days and excess lacrimal secretion ceased within 2 days. After the first application all patients experienced a soothing feeling in the infected eye and irritation and tenderness around the eyes disappeared within a few minutes. No adverse reactions were reported.

#### 25 Example 21 - Gum infections

Twenty-two patients with acute or chronic gum infections/inflammations were included in this study. Three times a day (morning, mid-day and evening) one of the ampoules of poly-enzyme preparation described in Example 1A was reconstituted in 5 ml tap water (yielding 5 Casein units/ml) and used to rinse a patient's mouth cavity for 5 minutes. No eating and drinking within 2 hours after treatment was allowed.

- 64 -

The treatment went on for 7 days independent of results. Pain relief was reported after 20 minutes to 12 hours of treatment. Infections and inflammations vanished within 4 days and did not reoccur during a follow-up period of 3 weeks. No adverse reactions were reported.

5 **Example 22A - Viral infections in the upper airways**

- Eleven patients with influenza virus infections and secondary bacterial infections in the upper airways, such as sinusitis, were included in this study. Viral infections in the lungs cause harm to lung cilia and inflammatory reactions that lead to erythema, swelling and increased mucus secretion. The
- 10 harmed cilia can no longer wipe away inhaled bacteria, which often leads to secondary bacterial infections. Viruses are dependent on host-cells for their survival and multiplication and it is difficult to kill a virus without harming or killing host cells. Prior to treatment, one of the ampoules of krill multifunctional hydrolase described in Example 1B was reconstituted in 5 ml
- 15 of saline to a final concentration of 5 Casein-Units per ml. 0.25 ml of this reconstituted solution was sprayed in each nostril and the mouth-cavity was rinsed for 5 minutes with 4.5 ml of the solution. The procedure was repeated three times daily and erythema, swelling, mucus-secretion, pain and adverse reactions were recorded once daily.
- 20 The treatment was continued until all signs of infection were gone but not for longer than 10 days. 8 patients were free from symptoms after 6 days of treatment and the remaining three patients after 9 days. Pain relief was experienced by all patients and occurred within 2 hours to two days. Sputum became clear within three days in patients with purulent discharges.
- 25 Erythema and swelling disappeared within 4 days. The results are summarized in Figure 7. No adverse reactions were observed.

**Example 22B - Common cold**

- Five patients in the age of from 30 to 63 years were treated with the krill multifunctional hydrolase according to Example 1B only a few hours after
- 30 the outbreak of the first cold symptoms. The treatment was carried out with

- 65 -

nasal sprays of 0.5 mg/ml aqueous solutions of the hydrolase (0.1 mg per nostril inhaled) every 4 hours and with 0.5 mg/ml mouth wash solutions (1.5 mg per wash) every 6 hours. The mouth wash solution was kept in the mouth for about 2-4 minutes and then swallowed. After 12 hours the  
5 common cold symptoms had disappeared and the patients were free of complaints.

**Example 23 - Haemophilus influenzae infections**

A woman of 34 had recurring sinusitis caused by infection of Haemophilus influenzae. A few hours after the appearance of the symptoms  
10 of pressure and pain in the nasal sinus, her mouth was washed for 3 minutes with 4.5 ml of a 5 mg/ml solution of krill multifunctional hydrolase according to Example 1B and 0.5 ml of the hydrolase solution was sprayed into each of her nostrils. This combined treatment was repeated three times at 2 hour intervals. After which, the spray treatment was repeated every three hours  
15 over a total of 3 days. The pressure caused by the nasal sinus infection disappeared within a few hours after the first treatment and the flow of nasal secretions strongly increased. After 3 days of treatment the woman was free of complaints.

**Example 24 - Bronchitis**

20 A 55 year old man having severe bronchitis complaints was treated. The man had respiration complaints, difficulty in walking more than 100 meters, severe tiredness, and a chronic hacking cough. His physician believed his bronchitis was caused by a mycoplasma which had first infected the patient 3 years earlier and had developed antibiotic resistance. The  
25 infection led to the formation of water in the pleura, as was verified by X-ray examination. The patient was treated with mouth washes containing 4 mg/ml saline of krill multifunctional hydrolase according to Example 1B. The hydrolase solution was kept in the mouth for about 4 minutes and then it was slowly swallowed. This treatment was repeated on every alternative day for  
30 the first two weeks of treatment. Also during this time, small amounts (0.5

- 66 -

ml) of an aerosol of the hydrolase solution was inhaled.

During the first two weeks no improvement was observed. After two weeks treatment the lymph gland on the left side of the patient's neck swelled, resulting in pain. Following this, the treatment was repeated about 3 times. About 1.5 weeks after this, the lymph node swelling had disappeared and the bronchitis complaints of the patient began to subside. After a further 3 weeks of treatment with mouth washes on every fourth day the bronchitis complaint had disappeared. After a treatment extending over 6.5 weeks the patient had recovered completely, and after a short time he could walk substantial distances without problems.

**Example 25A - Gastric ulcer**

A man of 40 having recurring complaints characteristic of a mild form of gastric ulcer was treated with acid-resistant gelatin capsules containing 5 mg of the krill poly-enzyme preparation of Example 1A per capsule. No filler was added to the encapsulated preparation. The patient swallowed 1 capsule a day with a glass of water for 2 weeks. After about 4 days the stomach complaints disappeared and the patient's intestines functioned normally.

A 55 years old man having recurring gastric ulcer complaints over 20 years was treated with the same dosage described above. After a few day's treatment the complaints had disappeared and his intestines worked normally.

**Example 25B - Colitis ulcerative**

The patient had a fifteen year medical history of Colitis Ulcerative, which had been treated with the antiphlogistic Salazopyrine (Pharmacia, Sweden). For six weeks she swallowed once daily an acid resistant capsule containing 1 mg of lyophilized, krill multifunctional hydrolase according to Example 1B. Concurrently she maintained her Salazopyrine treatment. Two hours after her first treatment with the multifunctional hydrolase, she experienced an attack of gastric pain, gas and diarrhea and these symptoms remained for approximately six hours. After her second treatment she experienced slight pain for about 30 minutes. After this, she experienced no

- 67 -

further adverse reactions. On days 16 and 29 she experienced gastric pain and diarrhea in connection with unusual meals. However, these episodes were shorter and less severe than her previous episodes. Through the course of the treatment, she recorded improved comfort. During the 3-4  
5 months following treatment, her symptoms slowly returned to the severity reported pre-treatment.

**Example 26 - Herpes genitalis**

A man of 62 having a long established case of Herpes genitalis was treated. Outbreaks recurred regularly every 4 months, and during acute  
10 outbreaks the man abstained from sexual intercourse. During an acute outbreak, the affected area was bandaged with a bandage soaked with a solution of krill multifunctional hydrolase according to Example 1B until it contained 3 mg of hydrolase. The bandaging treatment was repeated twice a day for 2 days. His complaints disappeared after the second treatment. The  
15 man had no outbreaks during the 10 months following treatment.

**Example 27 - Herpes simplex infection in the mouth cavity**

Eight patients with relapsed herpes simplex blisters in the mouth cavity were treated twice daily with mouth-wash. Prior to use, each ampoule of krill poly-enzyme preparation (described in Example 1A) was reconstituted in 5 ml  
20 of saline to a final concentration of 5 Casein-Units/ml. The patient rinsed his or her mouth cavity with the solution for 5 minutes. No eating or drinking was allowed within 2 hours after each treatment. The procedure was repeated twice daily and clinical parameters, erythema, swelling, pain and adverse reactions were recorded once daily. The treatment was continued  
25 until all signs of infection were gone, but not for longer than 10 days.

Pain relief was experienced within 2 hours after the first treatment. In some patients the pain recurred between treatments during the first two days, but never thereafter. After 5 days, all patients were free from symptoms and all blisters had healed. No adverse reactions were observed.

**Example 28 - Herpes zoster**

- A 70 year old man who had had a very painful herpes zoster infection in his face for 10 months was treated topically with a gauze bandage soaked to absorb a solution containing 1-2 mg of krill poly-enzyme preparation of
- 5 Example 1A every three days. After the first treatment the itch and pain were reduced. The pain disappeared completely after 12 days. Due to the pain associated with the infection, the man had had difficulties in chewing, but after 12 days he was able to chew food with no problems.

**Example 29 - Acne**

- 10 Two women, aged 29 and 30 years, were treated for facial acne. The 29 year old woman had severe acne, whereas the 30 years old woman had moderate acne. The patients were treated with 0.1 mg of krill multifunctional hydrolase according to Example 1B several times a day for 4-6 days by applying 0.5 g/cm<sup>2</sup> to 2 g/cm<sup>2</sup> of a hydrogel (described in Example 1F)
- 15 containing 5 mg/ml of krill multifunctional hydrolase. Improvement was apparent after the first treatment, and after a week of treatment only pigment traces of the acne were evident.

**Example 30 - Psoriasis and dry eczema**

- 20 Psoriasis plaques and dry eczema plaques were readily decomposed with hydrogel (described in Example 1F) preparations of the krill multifunctional hydrolase according to Example 1B. 0.5g/cm<sup>2</sup> of hydrogel (described in Example 1F) containing 5 Casein Units/ml hydrolase was applied to the sites in need of treatment and the site was covered with a semi-occlusive dressing. The treatments were repeated two times daily.
- 25 Within 24 hours the plaques were completely gone and the sensitive skin, especially in psoriasis patients, showed reduced inflammation. Following treatment, the affected areas were responsive to steroid creams.

**Example 31A - Eczema infections**

- Forty patients with eczematous seborrheic and psoriasis infections
- 30 were treated once to twice daily with poly-enzyme hydrogel (described in

- 69 -

Example 1F) containing 2.5 Casein Units/ml of the poly-enzyme preparation of Example 1A. Patients with dry eczema/plaque showed no signs of inflammation or infection after 2-4 treatments. The fatty type of seborrheic plaques disappeared after 6-9 days, though the associated

- 5 inflammations/infections had vanished within the initial 2-4 days of treatment. Patients with psoriasis plaque experienced an improved responsiveness to steroid creams, probably due to removal of plaque by the poly-enzyme preparation, resulting in better access to the skin.

**Example 31B - Lichen planus - with associated infection**

- 10 The patient suffered from lichen planus of the lower gum. The affected areas showed papules and lesions, and were covered with yeast plaque. Each day at that time 1 g of a hydrogel (described in Example 1F) containing 0.5 mg/ml of krill multifunctional hydrolase according to Example 1B was applied to the affected areas. After three days, the plaques and papules were gone.
- 15 On day 7, all lesions were healed and the treatment was stopped.

**Example 32 - Thrombolytic /anti-embolic properties**

- Thrombi were caused by applying an artificial stasis to the main ear vein of a rabbit until a proper thrombus had developed. krill multifunctional hydrolase according to Example 1B was injected (0.5 mg dissolved in 0.2 ml
- 20 of isotonic solution), into the ear vein in the direction of the thrombus, at a location 2 cm from the ischemic area. Within 30 minutes the thrombus had completely dissolved and the blood had free passage. Small necroses developed in the treated area but these were resorbed within 7 days. In the control animals the ischemic area turned necrotic within 4-5 days.

25 **Example 33 - Dental plaque in dogs**

- The krill poly-enzyme preparation was used to remove dental plaque in beagles. Before use, ampoules of the poly-enzyme preparation (described in Example 1A) were reconstituted in 5 ml of saline to a final concentration of 5 Casein-Units/ml. The content from a freshly prepared ampoule was carefully
- 30 painted over teeth and gingiva. The tongue was fixated for 2 minutes and



- 70 -

food and beverage were not allowed for 2 hours post-treatment. The treatment was repeated twice daily until all plaque was completely decomposed. The dogs were inspected for status of plaque, saliva secretion and adverse reactions once daily. Eight beagles with abnormal plaque formation due to special feeding and housing were included in this study. After 4 days all signs of plaque were gone and the study was terminated. No adverse reactions could be observed.

#### Example 34 - Human dental plaque

The krill poly-enzyme preparation was used to remove dental plaque in humans. One ampoule of poly-enzyme preparation of Example 1A was reconstituted, in 5 ml of saline to a final concentration of 5 Casein-Units/ml, before each treatment and used to rinse the patient's mouth cavity for 5 minutes. Food and beverage were not allowed for 2 hours post-treatment. The treatment was repeated twice daily and the patients were inspected once daily for plaque, saliva secretion, dryness, and adverse reactions. The patients were not allowed to brush their teeth during the study period. The treatment was continued until all signs of plaque were gone, but not for longer than 7 days. Two hours after the first treatment all patients experienced a soft and smooth sense over their teeth but visual inspection showed remnants of plaque. Two hours after the third treatment, all signs of plaque were gone and treatments were terminated. No adverse reactions were observed.

#### Example 35 - Cancer

The krill poly-enzyme preparation of Example 1A was used to treat Yoshida Sarcoma tumors in juvenile rats. Yoshida sarcoma cells are described in Micotina et al., *Tumour Biology*, 12: 225, 1991, and Goseki et al., *Cancer*, 69: 1865, 1992. The poly-enzyme preparation was administered by three different routes (intraperitoneally (i.p.), intratumorally (i.t.) and subcutaneously (s.c.)) to white Wistar rats that had been implanted Yoshida Sarcoma cells. The treatment groups were as follows:

- 71 -

- A. A single administration i.p. of 5 mg/kg.
- B. A single administration i.t. of 5 mg/kg.
- C. A single administration s.c. of 5 mg/kg.
- D. Twice daily administration s.c. of 1.25 mg/kg for seven days.
- 5 E. S.c. administrations of 5 mg/kg on four alternating days.
- F. S.c. administrations of 12.5 mg/kg on four alternating days.

Before use, ampules of the poly- enzyme preparation powder were reconstituted in isotonic saline at a concentration of 5 mg/ml solution. 1 x 10<sup>4</sup> Yoshida Sarcoma cells were implanted subcutaneously on the back of  
10 white Wistar rats. When the implanted cells had generated a 10 mm x 10 mm tumor, the rats were either treated with poly-enzyme preparation or used as untreated controls. The rats were sacrificed 7 days after the last treatment. The size of the tumors was measured and compared with the tumors of untreated control rats.

15 The relative reduction of the size of the tumor was 46% for group A, 56% for group B and 49% group C. In the group treated with repeated doses of 1.25 mg/kg twice a day over 7 days (group D), the reduction was 72%. In the groups receiving 5 mg/kg and 12.5 mg/kg s.c. every second day (groups E & F), the tumor reductions were 53% and 69%, respectively. In all treated  
20 rats, the portion of the tumors that was necrotic was substantially higher than for tumors from untreated rats. Also, the treated rats gained weight more rapidly than did untreated rats.

One rat in the group receiving 12.5 mg/kg every second day showed an absolute loss of tumor mass (rather than a relative loss). The degree of  
25 metastasis in the treatment groups was very small compared to the control rats. The treated rats showed normal behavior regarding drinking and eating, in contrast to the control rats, which were subdued and exhibited no appetite. No adverse reactions could be observed during this trial.

- 72 -

**Example 36 - Anti-viral effect on HIV-contaminated cell lines, in vitro**

The krill multifunctional hydrolase was tested for anti-HIV using the National Cancer Institute's standard assay. See Weislow et al., J. Natl. Cancer Inst. 81:577-586, 1989. The procedure comprises:

- 5           (1) The multifunctional hydrolase according to Example 1C was dissolved in dimethyl sulfoxide, diluted 1:100 in cell culture medium, and then subjected to serial dilutions. Virus infected T4 lymphocytes (CEM cell line) were added to the various dilutions. Matched controls comprise uninfected cells treated with the hydrolase for HIV-infected cells parallelly treated  
10 without the presence of the multifunctional hydrolase.

(2) The cell cultures were incubated at 37°C under 5% carbon dioxide atmosphere for 6 days.

- (3) Tetrazolium salt, XTT, was added to the culture wells, and the cultures were incubated to allow color development by viable cells. Four of  
15 the cultures were analyzed spectrophotometrically and microscopically to quantitate the number of viable cells present. Figure 8 shows a run of the assay. Line A is for the cells treated with multifunctional hydrolase, while Line B is the uninfected control. No activity is seen until concentrations in excess of 10 µg/ml, at which point a sharp transition in activity occurs and  
20 the hydrolase begins to show near total protective activity. The concentrations at which the hydrolase shows substantial protection are at least ten-fold less than the blood serum concentrations known to be safe.

**Example 37 - Grey cataract in dog**

- The right eye of a dog suffering from grey cataracts was treated with 2  
25 drops of a 5 Casein Unit/ml solution of the poly-enzyme preparation of Example 1A. The left eye was identically treated except that a 3 Casein Unit/ml solution of the multifunctional hydrolase according to Example 1B was used. The procedure was repeated once daily for each eye and the dog was inspected for changes in opacity and adverse reactions. After 5 days an  
30 obvious diminishing in the opacity could be noted in both eyes and after 10

- 73 -

days both eyes looked very clear and the treatment was terminated. No adverse reactions were observed.

**Example 38 - Cataract in human**

5 A woman in her 80's with day/night vision on one eye due to gray  
cataract was treated every three days with 0.4 ml of solution a 0.1 mg/ml of  
the poly-enzyme preparation of Example 1A. After 5 treatments the study  
had to be terminated due to other medical reasons but an obvious reduction in  
opacity was observed and the lady reported improved vision on the affected  
eye. No irritation, pain or other discomfort could be observed during the  
10 treatment or 1 month post-treatment.

**Example 39 - Glaucoma**

A man, age 74, experienced a slight pain/discomfort in the right eye  
and it was found that he suffered from an increased intraocular pressure that  
was found to be permanent and not caused by acute reasons. Every four  
15 days a solution containing 0.1 mg of the poly-enzyme preparation of Example  
1A was dropped into the affected eye for a total of three times. Two weeks  
post-treatment the intraocular pressure was normal and remained normal 4  
months post-treatment. The man experienced immediate pain relief, within  
20 minutes, at the first treatment. No adverse reactions were observed.

20 **Example 40 - General Purpose Eye Drops**

Twelve patients with no record of eye diseases, allergic reactions to air  
pollutants or eye infections/inflammation were treated for "tired and irritated  
eyes". Two drops of a 0.1 Casein Unit/ml solution of the poly-enzyme  
preparation of Example 1A were dropped into the eyes whenever needed. All  
25 patients experienced an alleviation of tension and pain within 30 minutes. No  
one reported any change in light sensitivity, focusing or any dilatation of the  
pupils. Occasionally a transitory dryness was experienced. No irritation,  
increase in lacrimal secretion or other adverse reactions were observed.

**Example 41 - Tendon-sheath adhesions**

30 The left Achilles tendon of each of two rabbits was ruptured and

- 74 -

immediately sutured in a split/overlapping technique. On Day 5 post-operation, there was an evident adhesion between the tendon and the tendon sheath. One mg of the poly-enzyme preparation (of Example 1A) dissolved in 0.25 ml was injected interstitially in the sheath on Day 5, Day 7 and Day 9 post-operation. One day (24 hours) after the first injection there was no evident adhesion between tendon and sheath. Six weeks post-operation the adhesion had not recurred. Eight months post-operation the animals were sacrificed and the tendons were macroscopically inspected for adhesions, surplus of fibrin and collagen. The tendons and sheaths had healed separately and no signs of adhesions could be observed. The tensile strength of the operated left leg tendons were compared to the unoperated right leg tendons and no difference could be detected. It is believed that the preparation specifically decomposed the surplus of fibrin without affecting the fibrin needed for a proper healing of tendon and sheath, respectively.

15 **Example 42 - Detachment of an adhered wrist**

A woman in her 40's suffered from a stiff wrist due to a long period of immobilization within a hard plaster cast. She exhibited about 25% of normal mobility. Despite a training program the mobility of the affected joint improved poorly and the diagnosis was fixation due to fibrin coating inside the joint. A solution of the poly-enzyme preparation of Example 1A was injected intraarticularly (2 mg/0.5 ml) every three days for a total of four injections. Joint mobility improved successively over 14 days to 50-60% mobility. The woman recovered a mobility to 70-80% after 4 months of rehabilitative training. No adverse reactions were observed.

25 **Example 43 - Decomposition of scars and keloids**

A solution of the poly-enzyme preparation of Example 1A was injected once daily into 5 facial scar formations and 3 keloid formations on hands and forearms. For every centimeter of the scar/keloid 0.2 ml of the solution (containing 5 Casein Units/ml) was injected to a maximum volume of 1 ml per scar or keloid per day. The procedure was repeated once daily and the

- 75 -

scar/keloid was inspected for erythema, swelling, heat, bleeding, necroses and adverse reactions. The treatment was terminated at 80% decomposition of scar/keloid but for no longer than 7 days. Fibrinous scars were reduced to 25% of their initial volumes and collagenous keloids to 70% after 7 days of treatment. No adverse reactions were observed during this trial.

**Example 44 - Wrinkle reduction**

A 33 year old woman was treated each night for 60 days by applying for 30 minutes a gauze bandage moistened with a solution of the multifunctional hydrolase according to Example 1B. The total amount of multifunction hydrolase used per application was 0.15 mg. The area below one of the patient's eyes was treated, while the other side was served as a control. After 15 days of treatment one could observe a difference in the elasticity of the skin and after 60 days of treatment there was a visually apparent difference in wrinkles. The treated skin area was very soft and elastic and the number and depth of the wrinkles had decreased considerably compared to the untreated skin area.

**Example 45A - Polyps**

A man of 62 having a polyp in his anus was treated. The man had suffered from the polyp for 3 years and had been treated by a physician. He had been treated with different kinds of medicines but no improvement was observed. He was treated with a gauze bandage containing about 5 mg of the multifunctional hydrolase according to Example 1B dissolved in 5 ml of saline. The treatment was repeated for a total of 5 times. All trouble disappeared and at the next visit to the physician it was observed that the polyp had disappeared. Eight months after the treatment, the man is still free of complaints.

**Example 45B - Warts**

A 35 years old man having a wart on his neck was treated for one week with a plaster ("Hansaplast") containing a solution of the multifunctional hydrolase according to Example 1B (0.1 mg/plaster). The treatment was

- 76 -

repeated daily for a week. After one week's treatment, the wart had completely disappeared.

**Example 45C - Hemorrhoids**

Two persons were treated for hemorrhoids, a man of 55 years and a  
5 woman of 30 years. The woman had had complaints for about 3 years with pain and minor bleedings. She was treated with dry powder of the multifunctional hydrolase according to Example 1B, which was wrapped in gauze bandage that was applied onto the area concerned. Each dose was 5 mg. Five treatments were needed before the patient's complaints  
10 disappeared. She was free of complaints for one year following the treatment.

The man had been troubled with hemorrhoids off and on for a number of years. When his symptoms, including bleeding and strong pain, became acute, the man was treated once with a gauze bandage soaked with about 4  
15 mg of the dry powder form of the multifunctional hydrolase according to Example 1B. The pain disappeared within about 20 minutes and after this single treatment all complaints disappeared and have not recurred since then.

**Example 46 - Treating infection in an infant's navel**

A 4 days old boy was treated with the multifunction hydrolase to  
20 remove necrotic tissue and to avoid upcoming infection. A gauze saturated with a solution of the multifunctional hydrolase according to Example 1B (2 mg/piece of gauze) was wound around the navel-string so that it covered both healthy, infected and necrotic navel-string tissue. The gauze bandage was changed 4 times every 12 hours. After about 12 hours, the treatment  
25 had removed the necrotic and the infected part of the tissue, whereas the healthy part of the navel-string was completely unaffected. No degradation of the healthy skin on the navel-string could be observed; neither could any infection or any skin irritation or inflammation be observed. The healthy navel was treated 4 more times. Day 6 after the birth the baby was checked at the  
30 hospital and it was found that the baby had a fine navel without any

- 77 -

infection, in contrast to the majority of the babies who were examined on the same occasion.

**Example 47 - Allergic itch**

A woman, age 28, had allergic problems in the form of intense itch  
5 with nettle rashes above one of the knees and also on and below the chin. The rash exhibited white, somewhat spread elevations on the knee whereas the chin was totally spotted with small rash of the same color as the skin. A gauze bandage was wetted with a solution containing 2 mg of the krill multifunctional hydrolase according to Example 1B. The gauze was applied to  
10 the rash on the area above the knee. After 10 minutes the gauze bandage was removed. 45 minutes later the itch began to fade out and had completely disappeared after 1.5 hours. The white elevations had also disappeared and the nettle rash had faded.

One day later the area under and on the chin was treated. This area  
15 now itched intensively and was more irritated than before owing to the woman's scratching. Directly upon application of the gauze bandage with the solution of krill multifunction hydrolase, the itch increased and the gauze bandage was removed after 7 minutes owing to a very intense itch. During the following 1.5 hours the itch declined and completely disappeared after  
20 2.95 hours. Two days after the initial treatment to the knees, no adverse reactions were observed on the treated areas.

**Example 48 - Prostatitis**

A man of 52 years suffered from prostatitis complaints each winter since the age of 20. During the last 4 years the complaints became more  
25 acute resulting in extremely severe abdominal pain. In every acute phase he was treated with different kinds of antibiotics but as soon as the antibiotic treatment was completed, the complaints recurred within about a week. During one episode, the man received acid-resistant capsules containing 5 mg/capsule of the dry form of the multifunction hydrolase according to  
30 Example 1B. He took 2 capsules/day for a week. All symptoms disappeared



- 78 -

and the man had no recurrence during the following 12 months.

**Example 49 - Mastitis (inflammation of the breast) in human**

A 28 years old mother of a newborn suffered severe galactostasis 3 days after delivery, the disease manifesting itself in hard, lactiferous glands and intense pain. These complaints set in half an hour after breast-feeding. She was hospitalized and treated with the standard methods available, but nothing helped. A solution containing 0.1 mg of the krill multifunction hydrolase according to Example 1B was dropped onto the nipple of the woman when the intense pain began. All pains disappeared within about 15 minutes and after about 45 minutes the hard lactiferous glands had become soft. This treatment was repeated after each breast-feeding for more than 3 months. To check the continuing need for the treatment, the woman occasionally refrained from treatment directly after breast-feeding. Each time this check was made the intense pains and the hard lactiferous glands recurred.

**Example 50 - Inflamed joints in horse**

16 lame trotters with inflamed foreleg knees were included in this study. Ampules of the poly-enzyme preparation of Example 1A were reconstituted in 10 ml water for injection at a final concentration of 2.5 Casein-Units/ml solution and 2 ml of the was injected into the painful joints of the trotters on Day 1, 2, 4 and 7. After the injections, the horses were observed for any adverse reactions or deteriorations in general condition. Clinical parameters were observed once daily. Nine cases responded with pain relief within 30 minutes to 2 hours after the first treatment, four more cases responded within 6 hours, and two more cases within 2 hours after the second injection. One case showed pain relief after the third injection and this case had an extreme swelling over the knee. Heat and swelling were reduced rapidly and no signs of inflammation could be observed after two days for 15 of the cases. No adverse reactions were observed. The averaged results are summarized in Figure 11. One week post-treatment the

- 79 -

horses were back on easy training.

**Example 51 - Tourist diarrhoea**

A 41 years old man acutely developed food poisoning (probably from Staphylococcus) with diarrhoea and vomiting. One hour after the man had fallen ill he was treated with a solution containing 5 mg of the krill multifunction hydrolase according to Example 1B by keeping it in the mouth for about 3 minutes, whereupon it was slowly swallowed. This procedure was repeated 3 times every other hour. After the fourth treatment the stomach pains had disappeared and the vomiting and severe diarrhoea had ended.

**Example 52 - Hair thinness**

Two men, 55 years old and 62 years old, respectively, were treated. They both had suffered from hair thinness for the last 10 years. The treatment was carried out by soaking the entire scalp with a solution containing 5 mg of the krill multifunction hydrolase according to Example 1B. To maintain the humidity in the scalp, it was covered with a shower cap for 30 minutes. The treatment was repeated once a week for about 3 months. After this time of treatment fresh hair began to grow out.

**Example 53 - Treatments with non-krill enzymes**

For each of Examples 8-52, the krill-derived multifunctional hydrolase is substituted with the multifunctional enzyme from another source and is comparably effective.

- 80 -

What is claimed is:

1. An enzyme, substantially purified, having a purity with respect to macromolecules of at least about 95%, and having multifunctional activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity, a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE, and substantial homology to krill-derived multifunctional hydrolase.
2. The enzyme of claim 1 having a molecular weight of from about 26 kd to about 32 kd as determined by SDS PAGE.
3. The enzyme of claim 1 having a molecular weight of about 29 kd as determined by SDS PAGE.
4. The enzyme of claim 1, wherein the enzyme is selectively reactive with cell-surface receptors.
5. The enzyme of claim 4, wherein the cell-surface receptors comprise cell-surface proteins or glycolipids.
6. The enzyme of claim 1 having purity of at least about 97% with respect to macromolecules.
7. The enzyme of claim 1 having purity of at least about 99% with respect to macromolecules.
8. The enzyme of claim 1 having purity of at least about 99.7% with respect to macromolecules.
9. The enzyme of claim 1 having an N-terminal sequence

- 81 -

comprising:

I-V-G-G-X-E/D-B-X-X-X-Z/B'-P-Z/H-Q-B-X-B'/Z,

wherein X is any amino acid, Z is an aromatic amino acid, B is an amino acid having a C2 to C6 alkyl side chain, and B' is leucine or isoleucine.

10. The enzyme of claim 9, wherein all amino acids represented by X, Z or B are natural amino acids.

11. The enzyme of claim 1 having an N-terminal sequence comprising:

I-V-G-G-X-E/D-B

wherein X is any amino acid, B is an amino acid having a C2 to C6 alkyl side chain.

12. The enzyme of claim 1 comprising the krill-derived multifunctional hydrolase.

13. The enzyme of claim 1 having the N-terminal sequence comprising:

I-V-G-G-N/M-E-V-T-P-H-A-Y-P-W-Q-V-G-L-F-I-D-D-M-Y-F (SEQ ID NO. 1).

14. The enzyme of claim 13 having a molecular weight of from about 26 kd to about 32 kd as determined by SDS PAGE.

15. The enzyme of claim 1 having at least about 70% homology with the krill derived multifunctional hydrolase

16. The enzyme of claim 15 having at least about 80% homology.

- 82 -

17. The enzyme of claim 15 having at least about 90% homology.
18. The enzyme of claim 15 having at least about 95% homology.
19. A pharmaceutical composition comprising the multifunctional enzyme of one of claims 1 to 18 and a pharmaceutically acceptable diluent or carrier.
20. A pharmaceutical composition for treating or preventing a microbial infection,  
said composition comprising a microbial infection treating or preventing effective amount of an enzyme according to one of claims 1 to 18.
21. The pharmaceutical composition of claim 20, wherein the microbial infection is viral.
22. The pharmaceutical composition claim 21, wherein the viral infection is a herpes, HIV, hepatitis, coronavirus, cytomegalovirus, rhinovirus or papilloma virus infection.
23. The pharmaceutical composition of claim 21, wherein the herpes infection comprises a HSV-1, HSV-2 or herpes zoster infection.
24. The pharmaceutical composition of claim 22, wherein the herpes infection is a genital herpes infection.
25. The pharmaceutical composition of claim 20, wherein the microbial infection causes a gastrointestinal disease.
26. The pharmaceutical composition of claim 25, wherein the

- 83 -

gastrointestinal disease is an ulcer or diarrhoea.

27. The pharmaceutical composition of claim 20, wherein the microbial infection is a fungal infection.

28. The pharmaceutical composition of claim 27, wherein the microbial infection is a systemic fungal infection.

29. The pharmaceutical composition of claim 27, wherein the microbial infection is a skin, oral, vaginal or esophageal fungal infection.

30. The pharmaceutical composition of claim 27, wherein the microbial infection is a fungal nail infection.

31. The pharmaceutical composition of claim 20 wherein the amount of the multifunctional enzyme has inhibitory activity against cell-cell or cell-virus adhesion.

32. The pharmaceutical composition of claim 20, wherein the microbial infection is an ocular infection and the composition is adapted for ocular administration.

33. A pharmaceutical composition for treating or preventing a dermatological condition,  
said composition comprising a dermatological condition treating or preventing effective amount of an enzyme according to one of claims 1 to 18.

34. The pharmaceutical composition of claim 33, wherein the dermatological condition is acne, psoriasis or eczema and the method comprises administering an acne, psoriasis or eczema treating or preventing

- 84 -

effective amount of the composition.

35. The pharmaceutical composition of claim 34, wherein the dermatological condition comprises eczema.

36. The pharmaceutical composition of claim 33, wherein the dermatological condition comprises hemorrhoids and the composition comprises a hemorrhoid treating or preventing effective amount of the multifunctional enzyme.

37. The pharmaceutical composition of claim 36, wherein the hemorrhoids are post-partum hemorrhoids.

38. A cosmetic composition for removing dead or peeling skin from otherwise healthy skin to improve the skin's appearance,  
said composition comprising a dead skin removing effective amount an enzyme according to one of claims 1 to 18.

39. A pharmaceutical composition treating or preventing a disease or cellular process selected from the group consisting of cancer, septic shock, tissue adhesions, malaria, immune disorder and apoptosis,  
said composition comprising treating or preventing effective amount of an enzyme according to one of claims 1 to 18.

40. The pharmaceutical composition of claim 39 for treating cancer comprising a tumor treating effective amount of the composition.

41. The pharmaceutical composition of claim 40 for preventing or limiting tumor metastases comprising a tumor metastasis preventing or inhibiting amount of the composition.

- 85 -

42. The pharmaceutical composition of claim 39 for treating or preventing tissue adhesions comprising an adhesion treating or preventing effective amount of the composition.

43. The pharmaceutical composition of claim 42, wherein the tissue adhesion is a tendon-sheath or abdominal post-surgical adhesion.

44. The pharmaceutical composition of claim 39 for treating or preventing an immune disorder comprising administering an immune disorder treating or preventing effective amount of the composition.

45. The pharmaceutical composition of claim 44, wherein the immune disorder is an autoimmune disease.

46. A pharmaceutical composition for lysing blood clots,  
said composition comprising a blood clot lysing effective amount of an enzyme according to one of claims 1 to 18.

47. A pharmaceutical composition for enhancing the healing of a wound,  
said composition comprising a wound healing enhancing effective amount of an enzyme according to one of claims 1 to 18.

48. The pharmaceutical composition of claim 47, wherein prior to application of the multifunctional enzyme, the wound is substantially free of necrotic tissue.

49. A pharmaceutical composition for treating or preventing a microbial wound infection,  
said composition comprising a microbial infection preventing effective



- 86 -

amount of an enzyme according to one of claims 1 to 18.

50. The pharmaceutical composition of claim 49, wherein the microbe is a drug-resistant microbe.

51. A pharmaceutical composition for treating or preventing acute or chronic inflammation,

said composition comprising an inflammation treating or preventing effective amount of an enzyme according to one of claims 1 to 18.

52. A pharmaceutical composition for treating or preventing an indication selected from the group consisting of pain, bronchitis, hemophilus influenza, mycoplasma in lungs, foreskin infections, athlete's foot, fistulae infections, infected topical ulcers, gastric ulcers, navel infections in newborns, wrinkles, polyps, scars and keloids, lichen planus, boils, warts and allergic itch, prostatitis, mastitis, gingivitis, sinusitis, arthritis and inflamed joints, diarrhoea, eye disease and hair-thinness,

said composition comprising a treating or preventing effective amount of an enzyme according to one of claims 1 to 18.

53. The pharmaceutical composition of claim 52, wherein the eye disease is glaucoma or cataracts.

54. A pharmaceutical composition for removing dental plaque, said composition comprising a dental plaque removing effective amount of an enzyme according to one of claims 1 to 18.

55. A method of purifying the a multifunctional enzyme having activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity, and a molecular weight between about 20

- 87 -

kd and about 40 kd as determined by SDS PAGE to obtain a composition containing substantially no other proteins that bind a selected protease inhibitor other than the multifunctional enzyme, the method comprising the steps of:

- (a) applying a composition containing the multifunctional enzyme to an ion exchange column;
- (b) eluting a first adsorbed material from the column with a first aqueous solution of first ionic strength  $I_1$ ;
- (c) eluting the multifunctional enzyme from the column with a second aqueous solution of second ionic strength  $I_2$ ;
- (d) applying the eluted multifunctional enzyme from step (c) to an affinity matrix comprising the protease inhibitor; and
- (e) eluting the affinity matrix with a third aqueous solution that destabilizes the interaction between the multifunctional enzyme and the protease inhibitor

wherein  $I_1$  is selected so that the first aqueous solution (i) elutes the first adsorbed material containing proteins that can bind to the protease inhibitor, but which proteins adhere to the anion exchange column more weakly than the multifunctional enzyme and, (ii) does not elute the multifunctional enzyme; and wherein  $I_2$  is greater than  $I_1$  and is selected so that the second aqueous solution elutes the multifunctional enzyme and substantially no other proteins that bind the selected protease inhibitor.

56. The method of claim 55 wherein  $I_1$  is about the ionic strength of 0.4M NaCl and  $I_2$  is about the ionic strength of 0.6 M NaCl.

57. The method of claim 55 wherein steps (b) and (c) are conducted at a pH between about 5.5 and about 7.5.

58. The method of claim 57 wherein steps (b) and (c) are conducted

- 88 -

at a pH of about 6.2.

59. The method of claim 55 wherein the ion exchange column comprises a cross-linked dextran and the ion exchange groups comprise diethylaminoethyl (DEAE) groups.

60. The method of claim 55, wherein the selected protease inhibitor used in the affinity matrix is resistant to digestion by the multifunctional enzyme.

61. The method of claim 60, wherein the protease inhibitor is mammalian trypsin inhibitor.

62. A pharmaceutical composition for preventing sexually transmitted microbial infection,

said composition or substance comprising a microbial infection preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

63. The pharmaceutical composition or substance of claim 62, wherein the sexually transmitted microbial infection comprises candida, gonorrhea, chlamydia, syphilis, trichomonas, chancroid, HIV, herpes, papilloma or hepatitis infection.

64. The pharmaceutical composition or substance of claim 62, wherein the microbial infection is vaginal candida infection.

- 89 -

65. The pharmaceutical composition or substance of claim 62, wherein the microbial infection is an HIV infection.

66. The pharmaceutical composition or substance for preventing a cold or influenza virus infection, said composition or substance comprising cold or influenza virus infection preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

67. A pharmaceutical composition or substance for treating or preventing a primary or secondary microbial infection in a patient having leprosy,

said composition or substance comprising a microbial infection treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

68. The pharmaceutical composition or substance of claim 67, wherein the microbial infection is an infection other than the infection causing leprosy.

69. A pharmaceutical composition or substance for treating a tissue, body fluid or composition of cells to remove or inactivate a cell adhesion component,

- 90 -

said composition or substance comprising a cell-adhesion removing or inactivating effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

70. The pharmaceutical composition or substance of claim 69, wherein the tissue, body fluid or composition of cells is treated with a immune rejection inhibiting amount of the enzyme.

71. The pharmaceutical composition or substance of claim 70, wherein the tissue, body fluid or composition of cells is treated extra-corporeally.

72. The pharmaceutical composition or substance of claim 70, wherein the tissue, body fluid or composition of cells is treated *in situ* in the body of an animal.

73. A composition or substance of cleaning a contact lens, said composition or substance comprising a multifunctional enzyme having: activity comprising a contact lens cleaning effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

74. The composition or substance of claim 73, wherein the

- 91 -

multifunctional enzyme composition is applied *in situ* in the eye.

75. A pharmaceutical composition or substance for treating or preventing a cell-cell or cell-virus adhesion syndrome,

said composition or substance comprising an anti-adhesion effective amount of a hydrolase effective to remove or inactivate a cellular or viral acceptor or receptor adhesion component that is involved in the cell-cell or cell-virus adhesion.

76. The pharmaceutical composition or substance of claim 75 wherein the syndrome comprises inflammation, shock, tumor metastases, autoimmune disease, transplantation rejection reactions or microbial infections.

77. The pharmaceutical composition or substance of claim 75, wherein (a) the disease is selected from the group consisting of microbial infection, immune disorder, cystic fibrosis, COPD, atherosclerosis, cancer, asthma, septic shock, toxic shock syndrome, conjunctivitis, reperfusion injury and pain, and (b) a cell surface receptor, associated with the cell-cell or cell-virus adhesion syndrome, selected from the group consisting of ICAM-1, ICAM-2, VCAM-1, CD4, CD8, CD11, CD18, CD28, CD29D, CD31, CD44, CD 49, CD62L, CD102 and asialo GM1 ceramide is removed or inactivated by the administered hydrolase.

78. The pharmaceutical composition or substance of claim 77, wherein the microbial infection is: a herpes, HIV, hepatitis or papilloma infection; an infection causing colitis, ulcer or diarrhoea; a candida infection; a cold or influenza infection; a *pseudomonas*, *haemophilus*, *staphylococcus*, *streptococcus*, *klebsiella* or *E. coli* infection; a primary or secondary infection of leprosy; or an infection causing conjunctivitis.

- 92 -

79. A pharmaceutical composition or substance for treating or preventing coronavirus, cytomegalovirus, rhinovirus or papilloma virus infection,

said composition or substance comprising an infection treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

80. The pharmaceutical composition or substance of claim 79, wherein the infection is a coronavirus infection causing feline infectious peritonitis.

81. The pharmaceutical composition or substance of claim 79, wherein the infection is a human papilloma virus infection.

82. A pharmaceutical composition or substance for treating or preventing HIV infection,

said composition or substance comprising an HIV infection treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

83. A pharmaceutical composition or substance for treating or preventing an oral or esophageal fungal infection,

- 93 -

said composition or substance comprising a fungal infection treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

84. A pharmaceutical composition or substance for treating or preventing lichen planus or a pseudomonas, candida, gonorrhea, chlamydia, syphilis, trichomonas, or chancroid infection,

said composition or substance comprising a microbial infection treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

85. The pharmaceutical composition or substance of claim 84, wherein the prevented or treated infection is a vaginal or oral candida infection.

86. A pharmaceutical composition or substance for preventing, diminishing or removing a corneal scar,

said composition or substance comprising a corneal scar preventing, diminishing or removing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial



- 94 -

homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

87. The pharmaceutical composition or substance of claim 86, for administering the multifunctional enzyme in conjunction with ocular surgery to prevent the formation of a corneal scar.

88. A pharmaceutical composition or substance for use in a method of treating or preventing conjunctivitis,

said composition or substance comprising a conjunctivitis treating or preventing effective amount (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

89. The pharmaceutical composition or substance of claim 88, wherein the conjunctivitis is viral, bacterial or allergic conjunctivitis.

90. A pharmaceutical composition or substance for treating or preventing a disease or cellular process selected from the group consisting of cystic fibrosis, COPD, atherosclerosis, asthma, toxic shock syndrome, reperfusion injury, colitis, enteritis and malaria-infection associated pain,

said composition or substance comprising a treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to

- 95 -

18.

91. The pharmaceutical composition or substance of claim 90, for treatment of a patient having cystic fibrosis or COPD, comprising a cystic fibrosis or COPD treating effective amount of the composition or substance.

92. The pharmaceutical composition or substance of claim 90, for treating or preventing atherosclerosis comprising an atherosclerosis treating or preventing effective amount of the composition or substance.

93. The pharmaceutical composition or substance of claim 90, for treating or preventing asthma comprising an asthma treating effective amount of the composition or substance.

94. The pharmaceutical composition or substance of claim 90, for treating septic shock or toxic shock syndrome comprising a septic shock or toxic shock syndrome treating effective amount of the composition or substance.

95. The pharmaceutical composition or substance of claim 90, for preventing or limiting reperfusion injury comprising a reperfusion injury preventing or limiting effective amount of the composition or substance.

96. The pharmaceutical composition or substance of claim 90, for reducing the pain associated with malaria infection comprising a malaria infection-associated pain reducing effective amount of the composition or substance.

97. The pharmaceutical composition or substance of claim 90, for treating or preventing colitis or enteritis comprising a colitis or enteritis

- 96 -

treating or preventing effective amount of the composition or substance.

98. A pharmaceutical composition or substance for treating or preventing an autoimmune disease,

said composition or substance comprising an autoimmunial disease treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

99. The pharmaceutical composition or substance of claim 98, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, lupus erythematosus, vasculitis, temporal arteritis, primary biliary cirrhosis, active chronic hepatitis, ulcerative colitis and scleroderma.

100. A pharmaceutical composition or substance for inhibiting or preventing the process of apoptosis,

said composition or substance comprising an apoptosis inhibiting or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

101. The pharmaceutical composition or substance of claim 100, wherein the cells are T-cells of HIV-infected patients.

- 97 -

102. A pharmaceutical composition or substance for treating or preventing post-partum hemorrhoids,

said composition or substance comprising a hemorrhoid treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

103. A pharmaceutical composition or substance for treating or preventing infection by a drug-resistant microbe,

said composition or substance comprising a drug-resistant microbial infection treating or preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

104. The pharmaceutical composition or substance of claim 103, wherein the microbe is a quinilone-resistant bacterium.

105. The pharmaceutical composition or substance of claim 103, wherein the microbe is a methicillin -resistant bacterium.

106. The pharmaceutical composition or substance of claim 103, wherein the microbe is a fungus.

107. The pharmaceutical composition or substance of claim 106,

- 98 -

wherein the fungus is resistant to azole-type drugs.

108. The pharmaceutical composition or substance of claim 107, wherein the fungus is resistant to fluconazole.

109. A pharmaceutical composition for removing or inactivating a cell-surface adhesion molecule comprising a cell-surface adhesion molecule removing or inactivating effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

110. A pharmaceutical composition for treating or preventing a cell-cell or cell-virus adhesion syndrome comprising a cell-cell or cell-virus adhesion syndrome treating or preventing effective amount of a composition comprising (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

111. The use of  
a composition comprising an enzyme according to one of claims 1 to 18 in the manufacture of a medicament to treat or prevent microbial infection.

112. The use of claim 111, wherein the medicament is to treat or prevent a viral microbial infection.

- 99 -

113. The use of claim 112, wherein the medicament is to treat or prevent a herpes, HIV, hepatitis, coronavirus, cytomegalovirus, rhinovirus or papilloma virus infection.

114. The use of claim 113, wherein the medicament is to treat or prevent a HSV-1, HSV-2 or herpes zoster infection.

115. The use of claim 113, wherein the medicament is to treat or prevent a genital herpes infection.

116. The use of claim 112, wherein the medicament is to treat or prevent a microbial infection that causes a gastrointestinal disease.

117. The use of claim 116, wherein the medicament is to treat or prevent gastrointestinal disease that is an ulcer or diarrhoea.

118. The use of claim 111, wherein the medicament is to treat or prevent a fungal infection.

119. The use of claim 118, wherein the medicament is to treat or prevent a systemic fungal infection.

120. The use of claim 118, wherein the medicament is to treat or prevent a skin, oral, vaginal or esophageal fungal infection.

121. The use of claim 118, wherein the medicament is to treat or prevent a fungal nail infection.

122. The use of claim 111, wherein the amount of the multifunctional

- 100 -

enzyme in each manufactured dosage form has inhibitory activity against cell-cell or cell-virus adhesion.

123. The use of claim 111, wherein the medicament is to treat or prevent an ocular infection and is manufactured for ocular administration.

124. The use of  
a composition comprising an enzyme according to one of claims 1 to  
18  
in the manufacture of a medicament to treat or prevent a  
dermatological condition.

125. The use of claim 124, wherein the medicament is to treat or prevent acne, psoriasis or eczema.

126. The use of claim 125, wherein the medicament is to treat or prevent eczema.

127. The use of claim 124, wherein the medicament is to treat or prevent hemorrhoids and the medicament is manufactured for application on the hemorrhoids.

128. The use of  
a composition comprising an enzyme according to one of claims 1 to  
18  
in the manufacture of a topical cosmetic composition to remove dead  
or peeling skin from otherwise healthy skin to improve the skin's appearance.

129. A topical cosmetic composition comprising a composition comprising an enzyme according to one of claims 1 to 18; and cream, gel or

- 101 -

suppository composition.

130. The use of  
a composition comprising an enzyme according to one of claims 1 to  
18

in the manufacture of a medicament to treat or prevent a disease or  
cellular process selected from the group consisting of cancer, septic shock,  
tissue adhesions, malaria, immune disorder and apoptosis.

131. The use of claim 130, wherein the medicament is for treating  
cancer.

132. The use of claim 131, wherein the medicament is for preventing  
or limiting tumor metastases by administering a tumor metastasis preventing  
or inhibiting amount of the multifunctional enzyme.

133. The use of claim 130, wherein the medicament is to treat or  
prevent tissue adhesions.

134. The use of claim 133, wherein the medicament is to treat or  
prevent tissue adhesion is a tendon-sheath or abdominal post-surgical  
adhesion.

135. The use of claim 130, wherein the medicament is to treat or  
prevent an immune disorder.

136. The use of claim 135, wherein the medicament is to treat or  
prevent an immune disorder that is an autoimmune disease.

137. The use of



- 102 -

18 a composition comprising an enzyme according to one of claims 1 to  
in the manufacture of a medicament to lyse blood clots.

138. The use of  
18 a composition comprising an enzyme according to one of claims 1 to  
in the manufacture of a medicament to enhance the healing of a  
wound.

139. The use of claim 138, wherein the medicament is to enhance the  
healing of a wound that is substantially free of necrotic tissue.

140. The use of  
18 a composition comprising an enzyme according to one of claims 1 to  
in the manufacture of a medicament to treat or prevent a microbial  
wound infection.

141. The use of claim 140, wherein the microbe is a drug-resistant  
microbe.

142. The use of  
18 a composition comprising an enzyme according to one of claims 1 to  
in the manufacture of a medicament to treat or prevent a acute or  
chronic inflammation.

143. The use of  
a composition comprising an enzyme according to one of claims 1 to

- 103 -

18

in the manufacture of a medicament to treat or prevent an indication selected from the group consisting of pain, bronchitis, hemophilus influenza, mycoplasma in lungs, foreskin infections, athlete's foot, fistulae infections, infected topical ulcers, gastric ulcers, navel infections in newborns, wrinkles, polyps, scars and kelloids, lichen planus, boils, warts and allergic itch, prostatitis, mastitis, gingivitis, sinusitis, arthritis and inflamed joints, diarrhoea, eye disease and hair-thinness.

144. The use of claim 143, wherein the medicament is to treat or prevent glaucoma or cataracts.

145. The use of claim 143, wherein the medicament is to treat or prevent pain.

146. The use of claim 143, wherein the medicament is to treat or prevent bronchitis.

147. The use of claim 143, wherein the medicament is to treat or prevent haemophilus influenza infections, mycoplasma of the lungs, foreskin infections, athlete's foot, fistulae infections, infected topical ulcers and navel infections in newborns.

148. The use of claim 143, wherein the medicament is to treat or prevent gastric ulcers.

149. The use of claim 143, wherein the medicament is to treat or prevent polyps, scars and kelloids.

150. The use of claim 143, wherein the medicament is to treat or

- 104 -

prevent boils, warts and allergic itch.

151. The use of claim 143, wherein the medicament is to treat or prevent proctitis.

152. The use of claim 143, wherein the medicament is to treat or prevent mastitis.

153. The use of claim 143, wherein the medicament is to treat or prevent gingivitis.

154. The use of claim 143, wherein the medicament is to treat or prevent sinusitis.

155. The use of claim 143, wherein the medicament is to treat or prevent arthritis and inflamed joints.

156. The use of claim 143, wherein the medicament is to treat or prevent diarrhoea.

157. The use of claim 143, wherein the medicament is to treat or prevent lichen planus.

158. The use of  
a composition comprising an enzyme according to one of claims 1 to  
18  
in the manufacture of a medicament to remove dental plaque.

159. The use of  
a multifunctional enzyme having: activity comprising at least one of a

- 105 -

chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent a sexually transmitted microbial infection.

160. The use of claim 159, wherein the medicament is to treat or prevent candida, gonorrhea, chlamydia, syphilis, trichomonas, chancroid, HIV, herpes, papilloma or hepatitis infection.

161. The use of claim 159, wherein the medicament is to treat or prevent vaginal candida infection.

162. The use of claim 159, wherein the medicament is to treat or prevent an HIV infection.

163. The use of  
a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to prevent a cold or influenza virus infection.

164. The use of  
a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a

- 106 -

molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent a primary or secondary microbial infection in a patient having leprosy.

165. The use of claim 164, wherein the medicament is to treat or prevent a microbial infection other than the infection causing leprosy.

166. The use of

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to extra-corporeally treat a tissue, body fluid or composition of cells to remove or inactivate a cell adhesion component.

167. The use of claim 166, wherein each dosage form of the medicament is manufactured with an immune rejection inhibiting amount of the enzyme.

168. The use of

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a contact lens cleaning composition.

- 107 -

169. The use of claim 168, wherein the multifunctional enzyme composition is manufactured for *in situ* use in the eye.

170. The use of

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent a cell-cell or cell-virus adhesion syndrome.

171. The use of claim 170, wherein the medicament is to treat or prevent inflammation, shock, tumor metastases, autoimmune disease, transplantation rejection reactions or microbial infections.

172. The use of claim 170, wherein (a) the medicament is to treat or prevent a disease selected from the group consisting of microbial infection, immune disorder, cystic fibrosis, COPD, atherosclerosis, cancer, asthma, septic shock, toxic shock syndrome, conjunctivitis, reperfusion injury and pain, and (b) each dosage form of the medicament is effective to remove or inactivate a cell surface receptor associated with the cell-cell or cell-virus adhesion syndrome selected from the group consisting of ICAM-1, ICAM-2, VCAM-1, CD4, CD8, CD11, CD18, CD28, CD29D, CD31, CD44, CD 49, CD62L, CD102 and asialo GM1 ceramide.

173. The use of claim 172, wherein the medicament is to treat or prevent a: a herpes, HIV, hepatitis or papilloma infection; an infection causing colitis, ulcer or diarrhoea; a candida infection; a cold or influenza infection; a *pseudomonas*, *haemophilus*, *staphylococcus*, *streptococcus*, *klebsiella* or *E.*

- 108 -

*coli* infection; a primary or secondary infection of leprosy; or an infection causing conjunctivitis.

**174. The use of**

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent a coronavirus, cytomegalovirus, rhinovirus or papilloma virus infection.

**175. The use of claim 1734 wherein the medicament is to treat or prevent a coronavirus infection causing feline infectious peritonitis.**

**176. The use of claim 174, wherein the medicament is to treat or prevent a human papilloma virus infection.**

**177. The use of**

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament for removing HIV infected T-cells from *ex-vivo* treated T-cells.

**178. The use of**

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a

- 109 -

molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent an oral or esophageal fungal infection.

**179. The use of**

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent lichen planus or a pseudomonas, candida, gonorrhea, chlamydia, syphilis, trichomonas, or chancroid infection.

**180. The use of claim 179, wherein the medicament is to treat or prevent a vaginal or oral candida infection.**

**181. The use of**

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to prevent diminish or remove a corneal scar.

**182. The use of claim 181, wherein the medicament is manufactured for use in conjunction with ocular surgery for preventing the formation of a**



- 110 -

corneal scar.

183. The use of

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent a conjunctivitis.

184. The use of claim 183, wherein the medicament is to treat or prevent viral, bacterial or allergic conjunctivitis.

185. The use of

a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent a disease or cellular process selected from the group consisting of cystic fibrosis, COPD, atherosclerosis, asthma, toxic shock syndrome, reperfusion injury, colitis, enteritis and malaria-infection associated pain.

186. The use of claim 185, wherein the medicament is to treat or prevent cystic fibrosis or COPD.

187. The use of claim 186, wherein each manufactured dosage form comprises a cystic fibrosis or COPD treating effective amount of the multifunctional enzyme.

- 111 -

188. The use of claim 185, wherein the medicament is to treat or prevent atherosclerosis.

189. The use of claim 188, wherein each manufactured dosage form comprises an atherosclerosis treating or preventing effective amount of the multifunctional enzyme.

190. The use of claim 185, wherein the medicament is to treat or prevent asthma

191. The use of claim 190, wherein each manufactured dosage form comprises an asthma treating effective amount of the multifunctional enzyme.

192. The use of claim 185, wherein the medicament is to treat septic shock or toxic shock syndrome.

193. The use of claim 192, wherein each manufactured dosage form comprises a septic shock or toxic shock syndrome treating effective amount of the multifunctional enzyme.

194. The use of claim 185, wherein the medicament is to prevent or limit reperfusion injury.

195. The use of claim 194, wherein each manufactured dosage form comprises a reperfusion injury preventing or limiting effective amount of the multifunctional enzyme.

196. The use of claim 185, wherein the medicament is to reduce the pain associated with malaria infection.

- 112 -

197. The use of claim 196, wherein each manufactured dosage form comprises comprising administering a malaria infection-associated pain reducing effective amount of the multifunctional enzyme.

198. The use of claim 185, wherein the medicament is to treat or prevent colitis or enteritis.

199. The use of claim 198, wherein each manufactured dosage form comprises by administering a colitis or enteritis treating effective amount of the multifunctional enzyme.

200. The use of  
a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase or an enzyme according to one of claims 1 to 18

in the manufacture of a medicament to treat or prevent an autoimmune disease.

201. The use of claim 200, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, rheumatoid arthritis, lupus erythematosus, vasculitis, temporal arteritis, primary biliary cirrhosis, active chronic hepatitis, ulcerative colitis and scleroderma.

202. The use of  
a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived

- 113 -

multifunctional hydrolase or an enzyme according to one of claims 1 to 18  
in the manufacture of a medicament to inhibit or prevent the process of  
apoptosis in cells at risk of apoptosis.

203. The use of claim 202, wherein the medicament is to inhibit or  
prevent apoptosis in T-cells from HIV patients.

204. The use of  
either (a) a multifunctional enzyme having: activity comprising at least  
one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase  
activity; a molecular weight between about 20 kd and about 40 kd as  
determined by SDS PAGE; and substantial homology to krill-derived  
multifunctional hydrolase; or (b) an enzyme of one of one of claims 1 to 18  
in the manufacture of a medicament to treat or prevent post-partum  
hemorrhoids.

205. The use of  
a multifunctional enzyme having: activity comprising at least one of a  
chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a  
molecular weight between about 20 kd and about 40 kd as determined by  
SDS PAGE; and substantial homology to krill-derived multifunctional  
hydrolase; or an enzyme according to one of claims 1 to 18  
in the manufacture of a medicament to inhibit or prevent infection by a  
drug-resistant microbe

206. The use claim 205, wherein the microbe is a quinilone-resistant  
bacterium.

207. The use claim 205, wherein the microbe is a methicillin-resistant  
bacterium.

- 114 -

208. The use of claim 205, wherein the microbe is a fungus.

209. The use claim 208, wherein the fungus is resistant to azole-type drugs.

210. A method of removing dead or peeling skin from otherwise healthy skin to improve the skin's appearance by applying a dead skin removing effective amount of a composition comprising an enzyme according to one of claims 1 to 18.

211. A method of removing dental plaque by applying a plaque removing effective amount of an enzyme according to one of claims 1 to 18.

212. A method of preventing sexually transmitted microbial infection comprising applying to a birth control device a microbial infection preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

213. The method of claim 212, wherein the sexually transmitted microbial infection comprises candida, gonorrhea, chlamydia, syphilis, trichomonas, chancroid, HIV, herpes, papilloma or hepatitis infection.

214. The method of claim 213, wherein the microbial infection is a vaginal candida infection.

215. The method of claim 213, wherein the microbial infection is an

- 115 -

HIV infection.

216. A method of cleaning a contact lens by applying to the lens a cleaning effective amount of a composition comprising (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to the krill-derived multifunctional hydrolase; or (b) an enzyme according to one of claims 1 to 18.

217. The method of claim 216, wherein the enzyme composition is applied *in situ* in the eye.

218. A birth control device comprising a microbial infection preventing effective amount of (a) a multifunctional enzyme having: activity comprising at least one of a chymotrypsin, trypsin, collagenase, elastase or exo peptidase activity; a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE; and substantial homology to the krill-derived multifunctional hydrolase or (b) an enzyme according to one of claims 1 to 18.




FIG. 1A




FIG. 1B

2 / 1 1




FIG. 2



3 / 11




FIG. 3

4 / 11

## MOT ASCITES GROWTH (Expt 4)




FIG. 4

5 / 11




FIG. 5




FIG. 6




FIG. 7

7 / 11




FIG. 8

8 / 11




FIG. 9

9 / 11

## Active Site Titration (pH 9.5)





FIG. 10

**FIG. 11** Average Pain Relief scoring over 7 days scoring with Multi-enzyme preparations from Krill.



#### Definitions

**Severe Pain:** Horse is not supporting itself on painful leg.

**Moderate Pain:** Horse is from time to time supporting itself on painful leg, more than 30 seconds each time.


**Mild Pain:** Horse is continuously supporting itself on painful leg, more than 2 minutes each time.



11/11

**FIG. 12** Decomposing efficacy of Single-enzyme preparation from Krill on necroses, fibrin, pus, and blood clots over 7 days treatment.

Percentage Black, Yellow and Red Tissues



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/01650

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : A61K 38/46, 38/48 US CL : 424/94.6, 94.63, 94.64, 94.67; 435/195, 212, 213, 219 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/94.6, 94.63, 94.64, 94.67; 435/195, 212, 213, 219 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA, BIOSIS, APS, WPI/DS search terms: krill and enzym?		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Turkiewicz, M. et al. Collagenolytic serine proteinase from Euphausia superba dana (antarctic krill). Comparative Biochemistry and Physiology. 1991, Vol. 99B, No. 2, pages 359-371, see entire document.	1-18, 73-74 -----
Y	WO 93/24142 (PHAIRSON MEDICAL) 09 December 1993, pages 1-48, see entire document.	19-72, 75-218
Y		1-218
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search 05 JUNE 1996		Date of mailing of the international search report 13 JUN 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>Richard F. Nease</i> JEAN C. WITZ Telephone No. (703) 308-0196